CoreWeave Stock Faces Fresh Pressure as Higher Rates Threaten AI Boom Summary
UBS lowered its CoreWeave price target to $105 from $120 but maintained its Buy rating, pointing to financing risks and weakening sentiment across AI stocks
CoreWeave CRWV shares dropped 2% in Friday morning trading as UBS cut its price target on the AI computing company to $105 from $120, while keeping its Buy recommendation.
The revised target reflects concerns about financing conditions and investor sentiment rather than a newly identified weakness in the company's operations. UBS analyst Karl Keirstead said demand trends, GPU pricing and CoreWeave's expansion into additional services remain supportive of its business outlook.
CoreWeave faces particular pressure when markets become less receptive to companies that need large amounts of capital. Building AI data centers requires substantial spending, while the company's negative free cash flow and reliance on debt make its valuation more sensitive to higher interest rates.
The stock's decline also comes amid broader uncertainty over how much companies will continue spending on artificial intelligence infrastructure. UBS views that wider reassessment as a key factor weighing on heavily funded AI businesses, rather than evidence that CoreWeave's own business prospects have suddenly weakened.
Although the bank retained its positive rating, the lower price target signals a more cautious view of the stock's near-term potential. Keirstead indicated that a recovery in investor confidence could take time as markets reassess AI investment and financing risks.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
ISELIN, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Middlesex Water Company (NASDAQ: MSEX) announced today that its Board of Directors has declared a quarterly cash dividend of $0.38 per share on its common stock, a 5.56% increase from the $0.36 per share dividend last declared in July 2026.
This increase raises the annual dividend rate to $1.52 from $1.44 per share of common stock and marks Middlesex Water Company’s (“Middlesex”) 54th consecutive year of dividend increases. The dividend at the new rate is payable December 1, 2026, to shareholders of record as of November 16, 2026. Middlesex has paid cash dividends in varying amounts each year since 1912.
About Middlesex Water Company
Middlesex Water Company (“Middlesex”) is one of the nation’s premier investor-owned water and wastewater utilities. Established in 1897, Middlesex is a trusted provider of life-sustaining services to more than half a million people in New Jersey and Delaware. The company focuses on employee engagement, operational excellence, superior customer experience, investment in infrastructure, and selective and sustainable growth to deliver value to our customers, investors, and the communities we serve.
Media Relations:
Rebecca Stenholm
Vice President, Communications and Corporate Affairs
[email protected]
(908) 565-2491
Investor Relations:
Jennifer Ketschke
Director, Investor Relations and Treasury
[email protected]
(732) 638-7523
From a valuation perspective, Syntec Optics Holdings, Inc. (OPTX - Free Report) stock looks expensive. OPTX is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 8.77X, above the industry average of 2.78X. OPTX also trades at a higher valuation compared to other industry players, such as Duos Technologies Group, Inc. (DUOT - Free Report) and Bit Digital, Inc. (BTBT - Free Report) . Currently, DUOT and BTBT trade at EV/sales multiples of 2.42X and 2.21X, respectively.
Image Source: Zacks Investment Research
While this elevated valuation reflects investor confidence in the company’s long-term potential, it also raises concerns about whether the stock can justify such lofty multiples. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.
OPTX Stock’s Price PerformanceSyntec Optics shares have jumped 135.3% over the past year against the industry’s 28.7% decline. The Zacks Business Services sector has fallen 14.4% while the S&P 500 has advanced 13.2%. Meanwhile, OPTX has outperformed DUOS and BTBT, which declined 36.8% and 76.8%, in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for OPTXSyntec Optics is benefiting from expanding demand for precision optics across U.S. defense platforms. In September 2026, the company reported more than $9 million in purchase orders, more than double its previously announced total. Demand spans missile-guidance optics, night-vision equipment, specialized targeting lasers and AI-enabled augmented-reality headsets. The breadth of applications and recurring orders could support production visibility as defense customers modernize their systems and deploy advanced optical technologies.
OPTX's space business is gaining traction through orders tied to national security and satellite communications. In September 2026, it secured an order for optics supporting U.S. Space Force infrastructure and reconnaissance satellites. The company is also ramping weekly shipments of precision waveguides for satellite antenna feeds. Management indicated that its space antenna portfolio could generate more than $1 million in annual revenues, while potential demand from expanding satellite constellations supports a longer-term opportunity.
Syntec Optics strengthened its lunar exploration exposure in October 2026 by announcing recurring production orders for precision components used in actuators on NASA's Artemis III rockets. These components help maintain engine positioning and flight trajectory. Management said the award increased its space technology backlog by 10%. The evolving mission plan, including orbital testing ahead of lunar operations, could provide additional production opportunities, although the timing and scale of future orders remain dependent on mission execution.
Syntec Optics is broadening its presence in AI infrastructure and advanced energy applications. In August 2026, it reported more than $4 million in orders linked to data center technologies and new fusion-energy orders valued at seven times those secured late in 2025. Its precision optics are designed for demanding fusion reactor environments, while micro-connectors and space-power systems expand the addressable product portfolio. Dedicating 5% of factory capacity to AI data center optics signals plans to build repeatable production in this market.
Improving financial flexibility could help Syntec Optics pursue its growing order pipeline. The company raised approximately $18.6 million in net proceeds through an April 2026 share offering and another $2.8 million from the underwriter's option exercise. It used roughly $6.8 million to repay debt and eliminated its bank credit line and related financial covenants. Sales increased to $14.8 million in the first half of 2026 from $13.6 million a year earlier, while operating cash flow improved to $0.2 million from $0.1 million.
Headwinds for OPTX’s BusinessSyntec Optics faces profitability pressures despite revenue growth. In the first half of 2026, gross profit declined to $3.1 million from $3.9 million a year earlier, as higher material costs, particularly aluminum, weighed on margins. The company reported a net loss of $0.6 million compared with nearly breakeven results a year ago. Customer concentration remains a concern, with three customers accounting for 52% of revenues. Competition from larger manufacturers, fluctuations in product mix and potential production disruptions could further pressure margins.
ConclusionOPTX’s growing defense and space orders, expanding AI infrastructure opportunities and improved financial flexibility support its long-term growth prospects. However, margin pressures, rising material costs, customer concentration and profitability challenges warrant caution.
Also, its valuation is higher than the industry average. For long-term investors, OPTX’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.
SummaryCerebras Systems Inc. has fallen 69% from its $386 peak, while Q2 core revenue still grew 103% year over year.RPO reached $25.4 billion, cash exceeded $8.6 billion, and management expects 2027 core revenue to more than triple.AMD integration could increase throughput around 5x, but customer deployment and real revenue conversion remain the key proof points.At $109, CBRS stock valuation still looks expensive today, but 2027 consensus sales imply a much lower 9.5x P/S multiple. NiseriN/iStock via Getty Images
With Cerebras Systems Inc. (CBRS) now around $109, I don't think it makes much sense anymore to discuss how expensive the stock was near $386. What matters to me now is whether this big decline has created an
8.78K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CBRS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
První skládací iPhone Duo od společnosti Apple s cenou 1 999 USD si vysloužil chválu recenzentů, uživatelé na Redditu však již hlásí praskání displeje v oblasti pantu.
Apple’s first foldable iPhone is drawing praise for its sleek engineering and nearly invisible screen crease — but critics say its hefty design, camera compromises and uneven app support make the $1,999 gadget a tough sell for most consumers.
On top of that, early reports indicate the pricey device may be prone to crack.
The iPhone Duo hits stores Friday after drawing an 8.8 out of 10 from Engadget and 7 out of 10 from both The Verge and WIRED.
An image posted by a Reddit user shows a damaged iPhone Duo. reddit/Bitter_Offer7123
Engadget called Apple’s long-awaited entry into the foldable market “worth the wait,” while The Verge described it as a “messy, expensive, good time.”
Meanwhile, Wired called it an “astonishingly good first foldable.”
The device unfolds to reveal a 7.6-inch matte display that dramatically reduces glare, while its innovative hinge operates smoothly and holds the screen at different angles.
However, a handful of Reddit posts indicated severe disappointment for some buyers as of Friday afternoon.
“iPhone Duo screen cracked within 6 hours of ownership,” one user complained.
The person said they had taken out the device to show it off to a friend when they “felt something around the internal hinge, underneath the screen.”
“As I continued opening it, I heard an audible crack, and the screen broke right along the hinge,” the post continued. “There were no marks or damage on the inner screen’s surface or the external hinge to suggest anything had been caught or damaged.”
The person zoomed back to an Apple store, where staff gave the customer a new Duo.
Another Reddit user posted a video of a cracked device, commenting: “Looks like some of them are cracking in the exact same area.”
Yet another image of a cracked Duo had the caption, “I’ve seen several iPhone Duos with damage in this exact same spot.”
A display of iPhone Duo smartphones is seen during a launch in Manhattan on Friday. Anadolu via Getty Images
Still, reviewers sung praises of the device’s titanium construction and smooth folding mechanism.
The crease hasn’t disappeared entirely, however. Several critics noted that it remains visible at certain angles and can still be felt when running a finger across the screen.
Apple’s anti-reflective finish also comes with a trade-off: Colors can appear less vibrant and blacks less deep than on the company’s non-folding premium iPhones.
At 254 grams and 11.3 millimeters thick when folded, the Duo’s bulk emerged as one of the most frequent complaints.
Its relatively small 5.4-inch outer display also drew mixed reactions, with some reviewers praising its compact footprint and others complaining that websites and apps feel cramped on the device.
The Wall Street Journal delivered one of the harshest assessments, describing the device as “Too Much iPhone, Too Little iPad.”
A display of iPhone Duo smartphones is seen during the launch in Manhattan on Friday. Anadolu via Getty Images
Despite its expansive inner display, the Duo falls short of an iPad when it comes to productivity, with more limited multitasking and keyboard capabilities, according to the Journal.
Software emerged as another major sticking point.
While Apple’s own apps generally make a seamless transition between the folded and unfolded screens, reviewers found that many third-party offerings weren’t properly optimized for the device.
Wired’s Julian Chokkattu described the problem: “Thick, black bars on the sides, with a phone-sized app in the middle of this tablet-like display.”
Engadget’s Sam Rutherford called the gap between optimized and unoptimized apps “the biggest growing pain you’ll face on Apple’s first foldable.”
Even the Duo’s multitasking capabilities have limitations.
Users can run two apps side by side, but Apple’s software restricts them to a fixed 50-50 split, without the freedom to open a third floating window.
Suraya Shivji, 28, a New York resident visiting San Francisco for a friend’s wedding, reacts to seeing the iPhone Duo in action at the Apple Union Square store in San Francisco on Friday. REUTERS
“If you have two apps split-screen on the Duo, Apple won’t let you resize one app to be slightly bigger than the other like you can on Android,” Chokkattu wrote in Wired.
“Here, a 50-50 split is always enforced. You can’t add a floating third app when in split-screen either, even though Apple has offered a similar capability on iPads for years.”
Those complaints could ease as developers adapt their apps to the new format.
Wired reported that several popular apps received updates during the device’s testing period, while Creative Strategies said the share of its installed apps optimized for the Duo increased dramatically over roughly six days.
Other shortcomings won’t be fixed with software updates.
“Despite being Apple’s most expensive iPhone, the iPhone Duo does not have its most powerful camera system,” Chance Miller of 9to5Mac wrote.
Its main and ultrawide cameras generally earned favorable marks, but several reviewers found their performance inferior to the iPhone 18 Pro, particularly in low light.
The hidden 4-megapixel camera beneath the inner display also disappointed, with Gizmodo reporting washed-out image quality.
An image provided by a Reddit user shows iPhone Duo models with damage in the exact same spot. reddit/robnaught
“I hear you: it feels absurd that a $2,000 phone—the most expensive iPhone ever—does not have the most versatile camera system that Apple has to offer,” Gizmodo’s Raymond Wong wrote, adding that he “noticed more lens flares coming off streetlights and more smeared details.”
Still, the folding design offers some novel photographic advantages, including the ability to use the higher-quality rear cameras for selfies while viewing the shot on the outer screen.
Battery life, meanwhile, exceeded the expectations of several reviewers, even if it couldn’t match Apple’s top conventional iPhone.
Tom’s Guide found that the Duo lasted 13 hours and 20 minutes in a continuous 5G web-browsing test using its larger display.
That handily beat the 10 hours and six minutes recorded by Samsung’s Galaxy Z Fold 8, but fell well short of the iPhone 18 Pro Max’s 17 hours and 31 minutes.
Other reviewers reported getting through a typical day without needing to recharge, although intensive use of the larger screen could drain the battery considerably faster.
The divergent ratings reflected less disagreement over the Duo’s strengths and weaknesses than differing views about whether its folding design justifies the compromises.
Tom’s Guide called it the “best designed foldable yet,” while 9to5Mac concluded that a conventional iPhone remains the more practical choice for most consumers.
Amazon AMZN stands out among consumer stocks as Bank of America (BofA) data show heavy withdrawals from consumer-focused funds, highlighting a divide between investor sentiment toward the broader sector and the quantitative appeal of individual companies.
Amazon received a quantitative score of 4.95 out of five in the supplied ranking, putting it at the top of the consumer-stock list. The scoring approach considers factors such as valuation, growth, profitability, earnings estimate revisions and share-price momentum relative to sector peers.
The broader fund-flow trend remains a concern. BofA's figures show consumer fund withdrawals accelerating, with the four-week moving average falling further into negative territory. That suggests investor caution may extend beyond short-term market fluctuations.
Amazon's diversified business spans online retail, cloud computing through Amazon Web Services, advertising and digital services. Those operations give the company several sources of growth, although a favorable quantitative score alone does not guarantee future share-price gains.
For investors, the key question is whether Amazon's business performance can continue to support its valuation while sentiment toward consumer-related investments weakens.
Amazon před zveřejněním výsledků čelí otázkám ohledně návratnosti investic do AI: tržby AWS ve 2. čtvrtletí vzrostly o 37 % a provozní zisk dosáhl 16,6 miliardy USD.
Amazon heads into Thursday's report after AWS operating income reached $16.6 billion, with AI investment returns in focus. -
Summary
AWS margins, capital spending and capacity constraints are key measures to watch.
Amazon, the commerce and cloud-computing giant AMZN, traded at $248.96, down 0.57%, at 10:00 a.m. ET ahead of Thursday's earnings report. The modest decline leaves the bigger question untouched: how much profit can Amazon squeeze from its AI infrastructure spending? Reuters' earnings preview frames the coming reports as a test of whether that investment can deliver durable returns.
The hurdle is already high. Amazon reported second-quarter AWS revenue growth of 37%, its fastest pace in 18 quarters, alongside $16.6 billion in cloud operating income. Companywide operating income climbed 43% to $27.5 billion. Management's third-quarter operating-income forecast of $22.5 billion to $26.5 billion puts the next report's profitability firmly in focus.
The GuruFocus snapshot shows a GF Score of 93/100, with growth its strongest category and financial strength comparatively weaker. That supports a strong operating profile, but it does not settle the spending question. Watch AWS margins, capital expenditures and capacity constraints together. Faster cloud growth carries more weight when the returns hold up after power, depreciation and chip costs.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Tržby AWS ve 2. čtvrtletí 2026 meziročně vzrostly o 36,7 % na 42,2 miliardy USD, což představuje nejrychlejší růst za 18 čtvrtletí, a to díky poptávce po AI.
Amazon survived a brutal 50% stock collapse, a CEO transition, and its first losing year in nearly a decade, then came roaring back with cloud growth nobody saw coming. Whether you bought in last year or ten years ago changes…
How an Online Store Became a Cloud and Ad Empire
A decade ago, Amazon (NASDAQ:AMZN | AMZN Price Prediction) was mostly an online store with a promising cloud side business. Over the decade that followed, AWS became the dominant profit engine, Prime grew alongside a huge logistics expansion, and advertising turned into a giant that brought in $19.8 billion in Q2 2026 alone, up 26%.
The pandemic sent e-commerce demand surging, and Andy Jassy succeeded Jeff Bezos as CEO in July 2021. Then the bill came due. Amazon overbuilt its fulfillment network, posted its first unprofitable year since 2014 in 2022, and the stock fell roughly 50%.
AI Pushed AWS Back Into High Gear
Cost discipline under Jassy brought margins back, and AI demand revived cloud growth. AWS revenue rose 36.7% to $42.2 billion in Q2 2026, its fastest growth in 18 quarters. The company’s AI and chips businesses each passed run rates of more than $25 billion.
Your $1,000 Grew to $5,966 Over the Decade
1-Year Return
Initial Investment: $1,000
Current Value: $1,148.80
Total Return: 14.88%
S&P 500 (same period): $1,140.90 (14.09%)
5-Year Return
Initial Investment: $1,000
Current Value: $1,499
Total Return: 49.9%
Annualized Return: 8.4%
S&P 500 (same period): $1,681.50 (68.15%)
10-Year Return
Initial Investment: $1,000
Current Value: $5,966
Total Return: 496.6%
Annualized Return: 19.6%
S&P 500 (same period): $3,545.60 (254.56%)
Timing explains almost everything here. The 10-year buyer got in before AWS and Prime fully took off and still finished well ahead of the index, even after sitting through the 2022 collapse. The 5-year buyer came in near the pandemic high, absorbed that same drop, and has trailed the S&P 500. Over the past year, Amazon roughly matched the market, and shares fell 4.57% on October 22 alone.
I Lean Bullish, With a Close Eye on Spending
I’d put $1,000 into Amazon today if AWS keeps turning its $496 billion backlog into high-margin revenue. Jassy says AWS could “very possibly be a trillion-dollar annual revenue business for us in time,” and advertising, grocery, and custom chips add growth that has nothing to do with cloud.
But I’d avoid it if spending exceeds the return. Amazon expects about $220 billion in 2026 cash capex, trailing free cash flow has turned negative at -$7.6 billion, and Anthropic gains boost GAAP earnings, including $53.4 billion pre-tax in Q2. At a P/E near 35, investors are paying up front for that expansion.
I lean bullish. The slow five-year stretch reflects a costly restructuring and a heavy investment cycle, and the AWS numbers suggest that cycle is starting to pay off. The next earnings report is the key test: I want AWS growth to hold up and capex to start bringing in revenue.
Contact [email protected] for any questions or corrections.
Akcionáři Canopy Growth schválili zmocnění představenstva ke konsolidaci akcií v poměru 1:5 až 1:15, o níž může představenstvo rozhodnout do 23. října 2027.
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsCanopy Growth NASDAQ: CGC shareholders approved all matters presented at the company’s reconvened 2026 Annual General and Special Meeting, including a share-consolidation authorization, the election of five directors and the appointment of MNP LLP as auditor for fiscal 2027.
The virtual meeting, which had been adjourned on Sept. 25, 2026, was reconvened on Oct. 23. Chief Executive Officer and Director Luc Mongeau chaired the session and said proxies representing enough common shares had been received to establish quorum.
Get Canopy Growth alerts:
Board Election and Auditor Appointment Constellation Brands: A Fallen Star or a Hidden Value Play?Shareholders elected all five board nominees: Mongeau, David Lazzarato, Theresa Yanofsky, Shan Atkins and Joseph Bayern. The directors will serve until the next annual general meeting or until their successors are elected or appointed.
Investors also approved the appointment of MNP LLP as Canopy Growth’s independent registered public accounting firm for fiscal 2027. The board, or an appropriate committee, was authorized to set the firm’s remuneration.
Profit from the Green Wave: Top Cannabis Stocks to WatchThe company presented its audited consolidated financial statements for the fiscal year ended March 31, 2026. No shareholder vote was required for the presentation of those financial statements.
Share Consolidation Authorized Among the approved proposals was a special resolution authorizing an amendment to Canopy Growth’s articles to consolidate its issued and outstanding common shares and exchangeable shares.
The board may determine the precise consolidation ratio, within a range of one post-consolidation share for every five to 15 pre-consolidation shares, at any time before Oct. 23, 2027. The same ratio would apply to common and exchangeable shares. Fractional shares resulting from the consolidation would be deemed tendered to the company for cancellation without consideration, as described in the company’s proxy statement.
Governance and Compensation Proposals Shareholders also approved an advance-notice bylaw establishing notice and other requirements for shareholders seeking to nominate directors at company shareholder meetings.
In addition, shareholders approved the renewal of unallocated awards under Canopy Growth’s omnibus incentive plan, including options, restricted share units, deferred share units, share-based awards and other entitlements.
The company’s advisory, non-binding say-on-pay proposal concerning named executive officer compensation also passed. Shareholders voted in favor of holding future advisory votes on executive compensation annually under the say-on-frequency proposal.
All director nominees were elected. MNP LLP was appointed as auditor for fiscal 2027. The board received authority to implement a share consolidation within the approved range. Shareholders approved the advance-notice bylaw and omnibus incentive-plan renewal. Investors supported executive compensation and selected an annual say-on-pay vote. Christelle Gedeon, Canopy Growth’s Chief Business Development and Corporate Affairs Officer and Corporate Secretary, said all items submitted to a ballot received the required shareholder approval. The company said final voting results, including votes cast for and withheld on each matter, would be reported through SEDAR+, a press release and a Form 8-K filing.
No questions were submitted by shareholders during either the formal-business portion of the meeting or the subsequent question-and-answer session.
About Canopy Growth (NASDAQ:CGC)Canopy Growth Corporation is a cannabis company headquartered in Smiths Falls, Ontario, Canada. Founded in 2013, the company operates in the production, distribution and sale of cannabis and cannabis-related products for adult-use and medical markets.
Its product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes, beverages and edibles. Canopy Growth markets products under several brands, including Tweed, 7ACRES, Doja and Deep Space, with offerings designed for different consumer preferences and product segments.
Canopy Growth primarily serves the Canadian recreational and medical cannabis markets and has pursued international opportunities in selected medical-cannabis markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Canopy Growth Right Now?Before you consider Canopy Growth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.
While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
SAP ve 3. čtvrtletí zvýšil objem budoucích cloudových kontraktů o 26 % na 24,1 mld. EUR při konstantních měnových kurzech; tržby z cloudu vzrostly o 25 %.
Enterprise software and business AI provider SAP SAP traded at $238.40, down 0.91%, at 10:24 a.m. ET on Friday. According to AD HOC News, BMO raised its price target to $265 from $235 and maintained Outperform. That puts the target roughly 11.2% above the share price. The analyst sees room to climb. Investors still need execution.
The business has momentum. SAP's third-quarter release reported €24.1 billion in current cloud backlog, up 26% at constant currencies, alongside 25% cloud revenue growth. Cloud ERP Suite revenue increased 28% on the same basis, while operating profit rose 18% under both IFRS and adjusted measures. Quarterly revenue topped €10 billion for the first time, and adjusted operating profit crossed €3 billion. Those milestones put real earnings behind the cloud story.
The valuation leaves something to prove. A GF Score of 90/100 signals broad fundamental strength, while a 29.15 price-to-earnings ratio makes sustained earnings growth central to the investment case. BMO's target increase amounts to 12.8%, but a higher target does not convert contracts into sales. The next test is whether SAP can turn its growing backlog into revenue while keeping profit growth strong.
FDA schválila společnosti AbbVie podkožní zahajovací režim přípravku SKYRIZI pro dospělé se středně až těžce aktivní Crohnovou nemocí, který umožňuje zahájit léčbu doma.
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
"People living with Crohn's disease need treatments that can deliver meaningful disease control from the start," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "With the approval of subcutaneous induction, we are building on the strong efficacy of SKYRIZI while giving patients and physicians greater flexibility in how treatment is initiated. This is one more example of how AbbVie continues to advance treatment to better meet the needs of people living with Crohn's disease."
Subcutaneous SKYRIZI Shows High Rates of Clinical Remission and Endoscopic Response by Week 12iii
This FDA approval is supported by positive results from the Phase 3 AFFIRM trial evaluating the efficacy and safety of SC SKYRIZI versus placebo in patients with moderately to severely active CD.iii SKYRIZI achieved superiority of the co-primary endpoints of clinical remission and endoscopic response at week 12.iii Although the study enrolled a primarily treatment-refractory population, these Phase 3 results were particularly strong within patients without prior advanced therapy failure (advanced therapy-naïve).iii By week 12, nearly three-quarters (74%) of advanced therapy (AT)-naïve patients were in clinical remission (vs. 27% placebo) and these AT-naïve patients achieved endoscopic response at four times the rate of placebo (60% vs. 15%, respectively).iii SC SKYRIZI also had a higher efficacy response in patients who had previously failed advanced therapy.iii
SC SKYRIZI also met secondary endpoints including endoscopic remission and FACIT fatigue scores at week 12 vs. placebo.iii The safety profile of SC SKYRIZI for induction was generally consistent with its known profile in CD, with no new safety risks observed.iii
Together, these results demonstrate market-leading clinical and endoscopic outcomes in advanced therapy-naïve patients that set a high bar in CD. Furthermore, the strength of these subcutaneous results provides a compelling foundation for future clinical trials.
AFFIRM Phase 3 Proportion of Patients Meeting Efficacy Endpoints at Week 12iii
Total Population
Prior Advanced Therapy
Failurea
Without Prior Advanced
Therapy Failureb
(Advanced Therapy-Naïve)
Proportion of
Patients
Placebo
N=94
Skyrizi SCc
N=180
Placebo
N=61
Skyrizi SCc
N=115
Placebo
N=33
Skyrizi SCc
N=65
Clinical
Remissiond,e
30 %
56 %h
31 %
45 %
27 %
74 %
Endoscopic
Responsed,f
15 %
43 %h
15 %
33 %
15 %
60 %
Endoscopic
Remissiong
11 %
26 %h
11 %
17 %
9 %
43 %
a. Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologic or Janus Kinase inhibitor (JAKi) treatments for CD
b. Without prior advanced therapy failure includes patients who were naïve to biologics or JAKi, or patients who had never failed or demonstrated intolerance to biologics or JAKi
c. SKYRIZI 720 mg as a subcutaneous injection at Week 0, Week 2, Week 4, and Week 8
d. Co-primary endpoints
e. Defined as Crohn's disease activity index (CDAI) < 150
f. Defined as a decrease in Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) > 50% from baseline, or a decrease of at least 2 points for subjects with a baseline
score of 4 and isolated ileal disease, based on central reading
g. SES-CD ≤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading
h. p <0.001 compared to placebo in total population.
Subcutaneous Treatment With SKYRIZI Offers Fully Self-Administered Therapy From the Start
The induction dosing regimen with SC SKYRIZI is 720 mg delivered by OBI induction pack at weeks 0, 2, 4 and 8.iii Patients also have the option to start treatment intravenously with 600 mg delivered at weeks 0, 4 and 8.iii Patients can then continue with maintenance dosing starting at week 12 administered by OBI every eight weeks.iii
"When patients and I discuss treatment, they want to know two things: will it work? And how will it fit into their lives?" said Millie D. Long, M.D., MPH, chief, division of gastroenterology and hepatology, University of North Carolina at Chapel Hill, and lead investigator of AFFIRM. "AFFIRM answered the first question, with superior rates of clinical remission and endoscopic response versus placebo during induction with subcutaneous SKYRIZI, particularly in patients new to advanced therapy. This approval answers the second. As a physician who has used the SKYRIZI OBI, I've seen firsthand the convenience it can offer patients. Now with this approval, patients can start treatment at home and continue the same way through maintenance."
Patients Report Satisfaction and Ease of Use in Real World Experience With SKYRIZI OBI
First introduced in 2022 for CD maintenance treatment, the SKYRIZI OBI has demonstrated strong user experience. In a real-world survey of 186 people living with CD, 88% reported AbbVie's OBI easy to use.v In evaluating alternative routes of administration, a patient-reported survey of 352 adults living with IBD found 87% were satisfied or highly satisfied with OBI compared to 71% with an autoinjectorvi, demonstrating patient preference for OBI.
FDA Also Approved Update to Tuberculosis (TB) Language in U.S. Prescribing Information
Additionally, the FDA approved an update to the SKYRIZI prescribing information's warning and precautions language across all approved indications.iii The revised label advises healthcare providers to consider TB evaluation prior to treatment initiation based on clinical judgment.iii This change gives healthcare providers greater flexibility in patient assessment before starting SKYRIZI treatment. There is no mandatory TB test prior to initiating SKYRIZI.
About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.vii,viii It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.ix,x Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.xi
About the AFFIRM Studyxii
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 274 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.xii More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).xii
Patient Access and Support
AbbVie is committed to helping people access SKYRIZI and other medicines, including offering a patient support program and co-pay card that may reduce out-of-pocket costs to as little as $0 per month for eligible, commercially insured patients. For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides SKYRIZI at no charge to those who qualify. More information about this assistance program can be found at www.AbbVie.com/myAbbVieAssist.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.iii SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.iii
SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationiii
SKYRIZI is a prescription medicine used to treat:
moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious side effects, including:
Serious allergic reactions:
Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded (low blood pressure) swelling of your face, eyelids, lips, mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 or visit http://glowpregnancyregistry.com to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/PatientAccessSupport to learn more.
Please click here for the Full Prescribing Information and Medication Guide.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
i. Co-primary endpoint defined as Crohn's Disease Activity Index (CDAI) score <150.
ii. Co-primary endpoint defined as decrease in SES-CD > 50% from baseline (or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline), as scored by a central reviewer.
iii. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
iv. Defined as CDAI of 220 to 450 and SES-CD ≥ 6 (or ≥ 4 for isolated ileal disease).
v. Keefer L, Griffith JM, Yang M, et al. Treatment satisfaction and patients' experiences with risankizumab on-body injector among adults with Crohn's disease in clinical practice: initial results from the ASPIRE-CD study. Poster P5425. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 24-29, 2025; Phoenix, AZ.
vi. Data on file, AbbVie Inc. Source: ZS Associates; December 2024-February 2025.
vii. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed October 13, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
viii. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
ix. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
x. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
xi. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
xii. ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Risankizumab Subcutaneous Induction in Participants With Moderately to Severely Active Crohn's Disease (AFFIRM). NCT06063967. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed October 13, 2026.
Palantir uvedl, že ani firma, ani americká vláda nemohou na dálku vypnout systém Maven, který NATO v roce 2025 pořídilo pro evropské vojenské velitelství.
Defense-AI software provider Palantir PLTR told Reuters that neither the company nor the U.S. government can remotely disable customers' Maven systems, as shares traded at $195.25, down 0.48% at 10:35 a.m. ET Friday. The statement addresses a central concern for European military buyers: who controls the technology once it is deployed?
According to Reuters' reporting, NATO purchased Maven for its European military headquarters in 2025 and declared full technical operating capability in June 2026. The platform brings together battlefield information from sources including satellites and radar. Palantir's latest reported quarterly revenue reached $1.94 billion, up 93%, with U.S. revenue rising 115% to $1.57 billion. That puts European adoption alongside an already fast-growing American business.
The valuation leaves little room for complacency. A GF Score of 83/100 sits alongside a price-to-earnings ratio of 166.31, suggesting solid business metrics come with demanding earnings expectations. Customer control addresses one technical concern, but governments still have to weigh sovereignty, security and oversight. For investors, the next meaningful signals are additional deployments, renewals and disclosed contract values. Those would show whether NATO's adoption translates into a broader European business.
SBS prověřuje možné porušení povinností vedení společnosti Roku vůči akcionářům v souvislosti s plánovaným převzetím společnosti Fox Corporation za 22 miliard USD, tedy 160 USD za akcii.
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Roku, Inc. (“Roku” or “the Company”) (NASDAQ: ROKU) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Roku board breached its fiduciary duties to shareholders. The Company to be acquired by Fox Corporation at an enterprise value of $22 billion, or $160 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Investors await next Thursday's results as strong prescription volumes face lower realized prices. -
Summary
Full-year revenue guidance stands at $85 billion–$87 billion.
Diabetes and obesity-drug maker Eli Lilly LLY traded at $1,284.51, down approximately 1.70% at 10.09am EST, on October 23. With earnings due next Thursday, according to Reuters' earnings preview, the key question is whether surging demand can keep overpowering weaker pricing.
Lilly's second-quarter results put that tension in numbers: revenue climbed 48% to $23 billion as volume increased 60%, while realized prices declined 13%. Mounjaro and Zepbound generated roughly $14.9 billion combined. Management raised its full-year revenue outlook to $85 billion–$87 billion, setting a demanding benchmark for the next report.
The valuation picture shows shares 19.01% below the GF Value estimate of roughly $1,590, suggesting potential upside against that model rather than a guaranteed bargain. Demand is powerful. Turning it into profitable growth remains the test. Investors should watch realized pricing, gross margin and manufacturing progress to judge whether higher prescription volumes are delivering enough earnings power.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Broadcom uzavřel s japonskou společností NTT DOCOMO desetiletou smlouvu na licence VMware, údržbu a technickou podporu pro privátní cloud připravený na umělou inteligenci. Finanční podmínky nebyly zveřejněny.
Semiconductor and infrastructure-software giant Broadcom
AVGO -0.48% 98
secured a 10-year VMware agreement with Japan's NTT DOCOMO, extending a major customer relationship. Shares traded at $326.075 on October 23, up approximately 0.88% at 10.45am EST on Friday. The investor question is straightforward: how much earnings power does that decade-long commitment bring?
The agreement covers software licenses, maintenance and technical support. Broadcom's announcement describes a relationship dating to 2019, with VMware Cloud Foundation underpinning DOCOMO's private cloud. The companies plan to improve reliability, security and deployment speed while preparing the platform for AI workloads. Financial terms were not disclosed, leaving investors without an annual contract value or a clear measure of its profit contribution.
The valuation snapshot puts Broadcom 24.74% below its $433.26 GF Value estimate, suggesting potential undervaluation rather than guaranteed upside. DOCOMO's commitment strengthens the customer-retention case for VMware, but contract length alone cannot establish attractive economics. The next proof points are infrastructure-software growth, cash generation and the cost of delivering support over ten years. AI readiness adds opportunity; meaningful incremental revenue still needs to follow.
Robinhood Markets (HOOD -1.56%) started with a simple idea: Make it easier for ordinary people to invest.
That sounds like a single business. But it isn't anymore. By the second quarter of 2026, Robinhood had 13 business lines generating at least $100 million of annualized revenue. That's up from just one in 2019 and nine in 2024.
At first, this might look like another impressive growth statistic. But digging deeper, I think it tells us something more important -- that Robinhood is getting better at turning one customer relationship into multiple sources of revenue.
Image source: Getty Images.
From one business to many Robinhood originally built its business around stock trading. But it didn't stop there. It kept adding products. Options became an important revenue stream. Crypto followed. Robinhood added margin lending, cash products, Gold membership subscriptions, securities lending, prediction markets, credit cards, etc. Each product gave Robinhood another way to make money from its customers.
That's an important strategy. A traditional broker might make money when a customer trades. Robinhood increasingly has opportunities to make money, whether that customer is trading, holding cash, paying for a subscription, using a card, borrowing against securities, or participating in other financial products.
The company doesn't need every product to become enormous. It needs enough of them to become meaningful. So far, that's happening.
HOOD Robinhood Markets$95.07-$1.51 (-1.56%)
NASDAQ · As of 4:00 PM ET 10/23/26
The customer matters more than the product This is where Robinhood's strategy is particularly important.
Imagine someone opens a Robinhood account to buy a few stocks. That customer might initially generate very little revenue. But over time, Robinhood can offer more products. The customer could subscribe to its Gold membership. Move more cash onto the platform. Trade options. Use the Gold Card. Buy crypto. Participate in prediction markets, and more. The customer doesn't need to find another financial company for each activity.
As for Robinhood, it can continue to expand the relationship, generating more revenue over time. Better still, it doesn't have to spend on customer acquisition costs, making growth highly efficient over time.
A few numbers show how customers are becoming more valuable. Robinhood ended the second quarter with 28.4 million funded customers, up 7% from a year earlier. Gold subscribers reached 4.8 million, up 39%, while average revenue per user increased 24% to $187.
That's an interesting combination. More customers. More products. More revenue per customer. If Robinhood can keep all three growing, the business could compound in ways that a simple trading platform cannot.
Diversification matters Another benefit of this strategy is that it reduces the volatility of Robinhood's traditional trading products. The idea is simple. Trading activity can be unpredictable. When markets become active, customers tend to trade more. When markets become quiet, transaction activity can slow.
Robinhood has gradually built other revenue streams that don't depend entirely on customers buying and selling stocks. In the second quarter, transaction-based revenue rose 44% year over year to $776 million. But Robinhood also generated $389 million of net interest revenue and $143 million of other revenue.
That mix gives the company more than one engine. If one product slows, another can potentially offset some of the weakness. That's especially valuable for a company whose original business depends heavily on market activity.
There's a catch that investors should understand, though. When Robinhood says a business has more than $100 million in annualized revenue, it doesn't mean the business generated $100 million in the past year. Robinhood calculates the figure by taking the relevant quarter's revenue and multiplying it by four. So, investors shouldn't treat the 13 businesses as 13 mature $100 million companies.
But the milestone still matters. It shows that Robinhood has created multiple products capable of reaching meaningful scale. Besides, the speed at which the company is building these products is remarkable, considering that it only had one $100 million product (options trading) in 2019.
What does it mean for investors? Robinhood has been in an expansion mode over the last few years, thanks to its strategy of building products that customers want to use. If it can continue to build products that customers want, the company could create a powerful flywheel: More customers give Robinhood a larger audience. More products give it more ways to monetize that audience.
Higher revenue gives Robinhood more resources to invest in new products. Successful products, in turn, make the platform more valuable to customers. That's how it can gradually become something much bigger.
In other words, the 13-business milestone doesn't prove Robinhood will become a great long-term compounder. But it gives investors an important clue on how the company is evolving, and that its long-term growth strategy is already gaining traction.
Akcie Chipotle v pátek klesly o 2,63 % na nové 52týdenní minimum 27,40 USD poté, co analytici snížili své cílové ceny kvůli obavám ze zpomalujícího růstu tržeb.
Chipotle Mexican Grill Inc. (NYSE:CMG) shares are sliding Friday. A fresh round of analyst price target cuts adds to concerns over slowing sales.
Chipotle Mexican Grill stock is testing key support levels. What’s pressuring CMG? Chipotle Stock Falls as Analysts Cut TargetsChipotle trades around $27.34, below its previous 52-week low of $27.87 and down from a 52-week high of $42.74. Chipotle has fallen around 2.81% today, extending a slide that totals approximately 8.50% over five days and 16.39% over a month. Over six months, the stock is down roughly 19.32%.
Evercore ISI Group analyst David Palmer lowered the price target to $40 Friday while keeping an Outperform rating.
More news today includes Mizuho analyst Nick Setyan, who also kept Outperform and brought the price target down to $37 from $43.
TD Cowen Downgrades Chipotle Over Slower SalesTD Cowen analyst Andrew Charles started the wave of cuts Wednesday with a downgrade to Hold from Buy and a lower price target of $32, down from $44.
Charles points to weak October demand as a threat to the fourth-quarter rebound that investors expect. Charles cautioned that sales are “slowing,” which raises questions about Chipotle’s ability to boost customer traffic and deliver on Wall Street’s 2027 growth hopes.
Street forecasts for 2027 call for same-store sales growth above 3%. Charles argues Chipotle may need untested levers, such as catering and more efficient restaurant equipment, to reach it, even with new menu items, marketing and loyalty programs.
Wells Fargo and Citigroup Also Cut TargetsWells Fargo analyst Zachary Fadem reduced the price target to $40 from $45 Wednesday and kept an Overweight rating. Citigroup analyst Jon Tower made a similar move Monday, lowering the target to $43 from $45 and maintaining Buy.
Benzinga’s consensus from 19 analysts is a Buy rating, with a $40.74 average target. Targets run from $32 to $53.
Chipotle releases third-quarter results on October 28, 2026. Wall Street models earnings of 29 cents per share, matching the year-ago figure, and sales climbing to $3.28 billion from $3 billion.
CMG Shares Are SlidingCMG Price Action: Chipotle shares were down 2.63% at $27.40 at the time of publication on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro.
Read Next
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Na společnost DICK'S Sporting Goods byla podána hromadná žaloba kvůli údajně zavádějícím informacím o akvizici společnosti Foot Locker; její akcie 25. srpna 2026 klesly o 30,68 %.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DICK's Sporting Goods, Inc. ("Dick's Sporting Goods" or the "Company") (NYSE: DKS) on behalf of investors that purchased or otherwise acquired Dick's Sporting Goods common stock between September 8, 2025 and August 24, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Dick's Sporting Goods and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On September 8, 2025, the first day of the Class Period, Dick's Sporting Goods announced the completion of its acquisition of Foot Locker, Inc. ("Foot Locker") for approximately $2.5 billion in cash and stock.
The complaint alleges that throughout the Class Period, Defendants misled investors regarding the Company's acquisition of Foot Locker, touting the acquisition as a strategic opportunity to drive growth and profitability while assuring investors that Foot Locker's longstanding inventory and promotional challenges had been resolved. In reality, according to the complaint, those problems persisted, as Foot Locker remained heavily dependent on legacy footwear products that were exposed to intensifying promotional pressures across the athletic footwear industry.
The truth was allegedly revealed to investors before markets opened on August 25, 2026, when Dick's Sporting Goods reported disappointing second-quarter 2026 results, which included revenue of $1.73 billion from Foot Locker that fell well short of analysts' estimates of $1.81 billion. Dick's Sporting Goods also reduced its net sales guidance for full-year 2026 and disclosed that it expected Foot Locker's proforma comparable sales to yield a range of negative 2.0% to 0.0% for the year-down from Dick's prior forecast of 1.5% to 3% growth.
On this news, the price of Dick's Sporting Goods stock fell $55.02 per share, or 30.68%, to close at $124.31 per share on August 25, 2026.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Shares of Comfort Systems (FIX -9.48%) fell as much as 13.2% on Friday, before recovering to an 8.9% decline at 3:10 p.m. EDT.
Comfort Systems reported earnings last night, handily beating revenue and earnings estimates. However, the company also announced that one of the company's founders and longtime Chief Financial Officer, Bill George, will retire at the end of the year.
During this earnings season, even good results are leading to stock declines for most companies levered to the AI build-out. Therefore, the retirement announcement, combined with a "sell the news" mentality, appears to be the cause of today's sell-off.
FIX Comfort Systems USA$1,158.11-$121.26 (-9.48%)
NYSE · As of 3:39 PM ET 10/23/26
Comfort Systems continues to thriveComfort Systems has been a massive winner due to the AI data center build-out, given its expertise in the cooling, plumbing, ventilation, and electrical systems that AI data centers require.
Third-quarter results continued that trend, with revenue growing a whopping 53.7% and earnings per share growing an even higher 68.6% to $13.91. Both figures beat analyst expectations by a fair amount.
Not only were current results terrific, but the company's backlog grew to $17.8 billion from $14.1 billion just three months prior. That's a 26.2% quarter-over-quarter growth rate in the backlog, which would amount to a 153.7% annualized rate.
This makes Comfort Systems' sell-off all the more confusing today. However, there have been many similar sell-offs this week in AI stocks, with blockbuster earnings often met with selling pressure. It appears some investors may be anticipating the end of the AI build-out next year, even as tech executives say the opposite.
Image source: Getty Images.
Comfort Systems is reasonably priced nowComfort Systems is now about 38% off its all-time high set back in June, while shares trade at 19.4 times the average 2027 analyst earnings estimate.
That's a very reasonable valuation for Comfort Systems if the AI build-out continues beyond 2027. However, doubts over that prospect, along with the CFO's retirement announcement, appear to be dominating sentiment today.
CoStar Group očekává ve 3. čtvrtletí tržby ve výši 935–945 mil. USD, což ve středu rozpětí výhledu představuje meziroční růst o 13 %, a upravený zisk na akcii ve výši 31–34 centů.
Key Takeaways CoStar Group expects Q3 revenues to grow 13% year over year at the midpoint.
CSGP's Q3 growth is likely to benefit from strong demand and rising subscriptions.
Improving margins may aid CSGP, while Ten-X weakness and pricing pressures pose risks.
CoStar Group (CSGP - Free Report) is slated to report third-quarter 2026 results on Oct. 27.
For the third quarter of 2026, CoStar Group expects revenues to be between $935 million and $945 million, representing a 13% year-over-year increase at the midpoint, and adjusted earnings of 31-34 cents per share.
The Zacks Consensus Estimate for third-quarter 2026 revenues is currently pegged at $950.99 million, suggesting growth of 14.08% from the year-ago quarter’s levels.
The consensus mark for third-quarter 2026 earnings has been unchanged at 34 cents per share over the past 30 days, suggesting a 47.83% increase from the year-ago quarter’s figure.
CoStar Group’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 21.17%.
Let us see how things have shaped up for CSGP before the announcement.
Factors to Note Ahead of CSGP’s Q3 ResultsCoStar Group’s third-quarter performance is likely to have been driven by strong demand for its commercial real estate information and analytics solutions, growing adoption of its residential marketplaces and improving operational efficiencies.
The company’s Commercial segment is expected to have benefited from increasing subscriptions to the CoStar platform, growing adoption of CoStar Debt Solutions and strong momentum in LoopNet’s paid listings. In the second quarter of 2026, CoStar Group’s revenues increased 9% year over year to $337 million, while LoopNet revenues rose 14% to $87 million. CoStar Group’s subscriber base expanded 19% to 327,000. For the third quarter of 2026, Commercial segment revenues are projected to be between $489 million and $494 million, indicating 7% year-over-year growth at the midpoint.
Residential segment performance is expected to have benefited from continued growth in Apartments.com, Homes.com and Domain. Apartments.com is likely to have gained from increasing paid property listings and strong customer retention, while Homes.com is expected to have benefited from expanding agent subscriptions and the introduction of its Platinum advertising tier. In the second quarter, Apartments.com revenues increased 9% to $318 million, while Homes.com revenues surged 66% to $28.5 million. For the third quarter, Residential segment revenues are expected to be between $446 million and $451 million, representing 20% year-over-year growth at the midpoint.
CoStar Group’s third-quarter profitability is expected to have benefited from disciplined expense management and improving residential operating leverage. The company expects adjusted EBITDA between $190 million and $210 million, implying an adjusted EBITDA margin of approximately 21% at the midpoint, up more than 700 basis points year over year. Commercial adjusted EBITDA is projected to be between $162 million and $172 million, while residential adjusted EBITDA is expected to be between $28 million and $38 million.
However, CSGP’s third-quarter 2026 results are expected to have been hurt by declining Ten-X transaction revenues, slower near-term growth at Homes.com due to sales-force restructuring and pricing pressures at Apartments.com amid intense competition and elevated multifamily vacancies.
What Our Model Says About CSGPOur proven model does not conclusively predict an earnings beat for CoStar Group this time. Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
CoStar Group presently has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they report earnings with our Earnings ESP Filter.
Stocks to ConsiderHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
Cadence Design Systems (CDNS - Free Report) , Seagate Technology (STX - Free Report) , and Amphenol (APH - Free Report) are some stocks with favorable combinations.
Cadence Design Systems has an Earnings ESP of +0.91% and carries a Zacks Rank #2 at present. CDNS is slated to report its third-quarter 2026 results on Oct. 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Seagate Technology has an Earnings ESP of +2.49% and sports a Zacks Rank #1 at present. Seagate Technology is set to report its first-quarter fiscal 2027 results on Oct. 27.
Amphenol has an Earnings ESP of +1.72% and a Zacks Rank #2 at present. Amphenol is set to report its third-quarter 2026 results on Oct. 28.
Archer Aviation plánuje sítě elektrických leteckých taxíků v Austinu, Dallasu–Fort Worthu a Houstonu, které mají zkrátit cesty autem trvající 60–90 minut na lety v délce 10–20 minut.
Archer Aviation Maps Out Ambitious Air Taxi Networks Across Three Texas Cities
Summary
Archer Aviation plans to develop electric air taxi networks across Austin, Dallas–Fort Worth and Houston, aiming to cut some road journeys from over an hour to as little as 10 minutes.
Archer Aviation ACHR shares slipped about 2% in Friday morning trading despite the company outlining plans for electric air taxi networks across Austin, Dallas–Fort Worth and Houston.
The proposed routes would connect major airports with commercial centers and popular destinations across the Texas Triangle, a region home to more than 20 million people. Archer sees the networks as a potential alternative to road travel in an area facing growing traffic congestion.
The company estimates its all-electric Midnight aircraft could reduce journeys that take 60 to 90 minutes by car to flights lasting just 10 to 20 minutes. The proposed service aims to make regional transportation faster while linking key business and travel destinations.
In Dallas–Fort Worth, the network would connect six airports with business locations, including Frisco Station. Houston routes would link three airports with a downtown hotel helipad and Galveston. In Austin, planned connections include two airports and the Circuit of The Americas racing venue.
Chief Executive Adam Goldstein said the proposed networks are designed to improve connections between major destinations and reduce time spent in traffic. The company did not provide a launch timeline in the supplied information.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Proti společnosti AST SpaceMobile (ASTS) byla podána hromadná žaloba kvůli údajně zavádějícím informacím o kapitálu a likviditě. Akcie 16. července 2026 klesly o 17,04 % na 55,01 USD.
Did you buy ASTS securities between March 4, 2025 and July 15, 2026?
Affected ASTS Investor Summary
Who: AST SpaceMobile, Inc. (NASDAQ: ASTS)What: Securities fraud class action lawsuit filedClass Period: March 4, 2025 through July 15, 2026Deadline to Seek Lead Plaintiff Status: November 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s capital and liquidity position.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against AST SpaceMobile, Inc. (AST) (NASDAQ: ASTS) on behalf of those who purchased or acquired AST securities between March 4, 2025 and July 15, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Texas and is captioned Hunter v. AST SpaceMobile, Inc., No. 7:26-cv-00378 (W.D. Tex.). Investors have until November 13, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired AST securities and have lost money on your investment, please provide your information here:
To view the AST video on YouTube, click here: https://youtu.be/Y3ho2nK1mZo?si=UWOeZxO1resG0YuO
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
AST SPACEMOBILE, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AST’s increasing capital requirements were likely to increase the company’s debt load and share dilution with greater frequency and at greater scale than Defendants had signaled to investors; (2) accordingly, AST had overstated the sufficiency of the company’s capital and liquidity position to achieve its strategic and business goals; (3) AST likewise overstated the durability of its competitive position in the satellite D2C market; (4) even following the EchoStar Transaction, Defendants continued overstating AST’s competitive position in the satellite D2C market; (5) AST was experiencing slow user adoption in the U.S. and Japan; (6) the foregoing was likely to have a significant negative impact on AST’s business and financial prospects; and (7) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Why did AST’s Stock Drop?
Between September 8, 2025 and July 15, 2026, a series of stock downgrades and company disclosures caused AST’s stock price to fall significantly. Specifically, on January 7, 2026, Scotiabank downgraded AST to sell, citing, among other things, significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites. Then, on July 15, 2026, AST issued a press release "announc[ing] the pricing of $1.0 billion aggregate principal amount of 1.625% convertible senior notes due 2034". Following these disclosures, AST’s Class A common stock price fell $11.30 per share, or 17.04%, to close at $55.01 per share on July 16, 2026.
WHAT AST SPACEMOBILE, INC. INVESTORS CAN DO NOW:
File to be lead plaintiff by November 13, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR AST SPACEMOBILE, INC. INVESTORS:
AST investors may, no later than November 13, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages AST investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Akcie LVMH, Kering a Hermès letos kvůli slabší poptávce v Číně klesly o 40 %; tržby těchto společností ve třetím čtvrtletí meziročně klesly o 2 %, 1 % a 2 %.
Stocks for some of Europe’s most famous luxury brands are plummeting to their lowest level in years as Chinese customers cut back purchases and an industry revamp fails to launch.
Shares are down a jaw-dropping 40% so far this year for the continent’s fashion stalwarts — LVMH, parent company of Louis Vuitton, Gucci and more; Kering, which owns brands including Gucci and Bottega Veneta; and independent-minded Hermès.
A widely reported drop in demand for luxury products — particularly among Chinese customers and international social climbers, sometimes called “aspirational shoppers” in industry lingo — is to blame for Kering’s woes, the Wall Street Journal noted.
A Gucci storefront where men’s flip-flops can cost $900. JHVEPhoto – stock.adobe.com
“We know we have a lot of work to do in China,” the conglomerate’s finance chief Armelle Poulou said on an earnings call.
Kering sales dropped 1% in the third quarter. LVMH and Hermès each saw a 2% decrease. At Gucci alone, sales were down 6%.
The drop comes as the Chinese economy has been taken a beating. While unemployment is up, property values and household spending have been trending downward, according to the Journal. The country recently saw its slowest GDP growth since 2022.
“Despite the recent share price weakness, we expect some further pressure on the space as a whole today, with confirmation that the Chinese cluster seems to have taken a material (and bigger than feared) step down,” said JP Morgan analysts said in a note to investors about LVMH, according to Reuters.
The stock decline has put a dent in LVMH kingpin Bernard Arnault’s fortune. He last topped Forbes’ list of billionaires in 2024, when he was worth $233 billion, but his wealth is listed at around $171 billion today, putting him in seventh place.
Meanwhile, LVMH-owned Zenith has started a consultation process that may lead to layoffs, according to Reuters.
Products display in 2024 at the Louis Vuitton fashion house at Marina Bay Sands shopping mall in Singapore. A mini bag can cost $2,000 or more. monticellllo – stock.adobe.com
A Hermes store in Munich in 2019. The brand’s coveted Birkin bag can sale for up to $53,000 auction price. EdNurg – stock.adobe.com
Customers in Asia, with China as the lead, account for a quarter of Kering’s sales.
An Hermès finance exec said the Chinese market – the company’s largest – was “very difficult.” Eric du Halgouet told reporters that he still remained confident about the Asian market and would “continue to invest,” according to Reuters.
There might be a shinier future for the prestigious brands. Analysts at Goldman Sachs Research are forecasting a 7% revenue increase for the luxury goods sectors as a whole for 2027.
“We view this as a solid recovery for an industry that has faced a prolonged period of sluggish performance,” wrote Erwan Rambourg, the group’s head of Europe luxury and lifestyle.
Smaller Gucci bags can go for around $900. However, Gucci heels can cost about $1,200. gpriccardi – stock.adobe.com
He expects more innovation and a reliance on different types of products. For instance, Gucci and L’Oréal have a 50-year exclusive beauty license that goes into effect in 2027.
Still, challenges include China’s property value woes, with new home prices losing 0.1% of their market value monthly, according to Reuters. Beijing recently announced subsidies for first-time mortgages to boost home sales, according to the Journal.
The stock decline has put a dent in LVMH kingpin Bernard Arnault’s fortune. REUTERS
Last month, luxury credit card spending dropped 6% year over year, according to Citi.
Still, LVMH said it was good third-quarter growth in Europe and the US as Chinese customers looked elsewhere.
Bank of America snížila doporučení pro NVR na „podprůměrný výkon“; objednávky nových domů ve 3. čtvrtletí meziročně klesly o 7 % a tržby z výstavby domů o 8 % na 2,35 mld. USD.
NVR Inc. (NYSE:NVR) received a downgrade from Bank of America on Friday as the investment firm warned that weakening homebuyer demand, rising construction costs and pressure on profit margins could weigh on the homebuilder’s earnings through 2027.
Bank of America analyst Rafe Jadrosich downgraded NVR from Buy to Underperform and lowered the price forecast to $5,900 from $6,725.
Jadrosich cited disappointing third-quarter results, slowing sales in key markets and concerns that NVR’s valuation remains elevated despite deteriorating fundamentals.
Weak Homebuyer Demand Raises ConcernsNVR reported third-quarter earnings of $89.45 per share, about 12% below Bank of America’s forecast of $101.53.
New home orders fell 7% year over year to 4,391, missing the firm’s estimate by 14%. The average selling price of new orders declined 4%.
Homebuilding revenue dropped 8% to $2.35 billion, while home deliveries fell 7%.
Jadrosich highlighted weakening demand in NVR’s core Mid-Atlantic markets, where the company has historically maintained a competitive advantage.
Philadelphia and Richmond slipped 10 and 13 positions, respectively, in Bank of America’s September housing market rankings. Baltimore and Virginia Beach also showed signs of weakness.
Mid-Atlantic orders declined 4%, while orders per community plunged 19% year over year.
The analyst said the slowdown was particularly concerning because NVR had previously maintained stronger sales momentum than many competitors.
Rising Costs Threaten Profit MarginsBank of America expects additional pressure on NVR’s margins as the company adjusts home prices to attract buyers while facing higher land, labor and construction costs.
NVR’s adjusted homebuilding gross margin contracted 246 basis points year over year to 19.3% in the third quarter. Its homebuilding operating margin fell 322 basis points to 13%.
Jadrosich warned that weaker sales could force NVR to offer more competitive pricing to maintain its home delivery schedule.
The company’s business model relies on options to purchase developed lots, which could create pressure to sustain sales volumes as land purchase commitments come due.
Meanwhile, higher lumber and transportation costs, along with persistent shortages of finished lots, could further weigh on profitability.
NVR’s vertical integration could also expose it to rising construction material costs earlier than some competitors.
Labor shortages have added another challenge. The company’s backlog conversion rate declined to about 48% from 56% a year earlier.
Earnings Forecasts Cut, Buybacks Expected to SlowBank of America lowered its 2026 and 2027 earnings estimates by 5% and 10%, respectively.
The firm now expects earnings of $345.39 per share in 2026 and $357.42 in 2027.
Jadrosich also expects NVR’s share repurchases to slow as weaker earnings and declining cash reserves limit its ability to sustain aggressive buybacks.
The company repurchased approximately $2.1 billion in shares in 2024 and $1.8 billion in 2025, exceeding its free cash flow in both years.
Bank of America forecasts repurchases of $1.4 billion in 2026, followed by $1.1 billion annually in 2027 and 2028.
The analyst also warned that stock-based compensation expenses could increase in 2027 if NVR resumes its traditional four-year stock option grant cycle.
Valuation Remains Elevated Despite Earnings WeaknessJadrosich said NVR’s valuation has become harder to justify as earnings expectations weaken.
Bank of America’s 2026 and 2027 earnings forecasts have declined 25% and 33%, respectively, since the beginning of the year. However, NVR shares have fallen only 16% over that period.
The stock trades at approximately 17 times projected 2027 earnings, above its historical average.
The revised $5,900 price forecast is based on 16.5 times estimated 2027 earnings, down from the firm’s previous valuation multiple of 17 times.
Despite acknowledging NVR’s strong market position and operating history, Jadrosich remains cautious until demand, land costs and profit margins show clearer signs of improvement.
NVR Price Action: NVR shares were down 0.81% at $6,060.96 at the time of publication on Friday, according to Benzinga Pro data.
Akcie společnosti CoreWeave (CRWV) v pátek klesly na nové 52týdenní minimum; vyšší úrokové sazby a obavy z výdajů na umělou inteligenci zhoršují důvěru v zadlužené poskytovatele cloudové infrastruktury.
CoreWeave Inc. (NASDAQ:CRWV) shares are breaking to a new 52-week low Friday, its second fresh low in days, as higher rates keep weighing on the stock.
CoreWeave stock is testing key support levels. Why is CRWV stock at lows? At roughly $54.28, CoreWeave trades below the $57.24 low it set earlier this week and about 62% beneath its 52-week high of $141.79. Today’s 1.43% decline adds to a long slide: around 10.72% over five days, 36.93% over a month and 53.32% over six months.
Morgan Stanley and UBS Cut CoreWeave TargetsMorgan Stanley analyst Keith Weiss stayed at Equalweight and reduced the price target to $70 from $99. Weiss credits CoreWeave with solid execution and calls it the “speed and scale leader” among crowded neocloud rivals. Still, financing uncertainty is obscuring how the company will deploy its contracted capacity and eventually reach 8 gigawatts of active capacity.
More news today includes UBS analyst Karl Keirstead, who held Buy and trimmed the price target to $105 from $120. Keirstead noted that CoreWeave has lost 37% in October as neocloud AI infrastructure stocks, Oracle among them, saw confidence erode.
Microsoft and Amazon moved higher instead, a split Keirstead takes as a defensive turn on AI infrastructure, and one UBS broadly shares. The note revisits CoreWeave’s credit story and warns that rebuilding confidence could be a “multi-quarter fix.”
Rising Rates Pressure Debt-Heavy CoreWeaveHigher interest rates are weighing on companies that carry heavy debt, alongside unease over AI spending, and CoreWeave is among them. Rates and AI spending worries have driven this week’s selling.
CNBC reported Wednesday that holders of CoreWeave stock and bonds are both losing confidence as rates climb and AI build-out doubts grow. Investors increasingly view debt-laden neocloud providers, CoreWeave among them, as the most vulnerable corner of AI.
CRWV Shares Are FallingCRWV Price Action: CoreWeave shares were down 1.13% at $54.97 at the time of publication on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro.
Read Next
Image: Mamun_Sheikh/Shutterstock.com
Market News and Data brought to you by Benzinga APIs
Planet Labs otevřela v Berlíně továrnu s kapacitou až 60 satelitů ročně, aby uspokojila rostoucí poptávku ze strany evropských vlád; tržby v regionu EMEA ve 2. fiskálním čtvrtletí vzrostly o více než 130 %.
Key Takeaways Planet Labs' new Berlin facility can produce up to 60 satellites annually to serve European sovereign demand.Defense and Intelligence revenues surged 93.3%, while EMEA revenues jumped more than 130% in Q2.PL expects $100-$115M in fiscal 2027 capex as weaker free cash flow raises concerns about returns.
Planet Labs PBC (PL - Free Report) is expanding its manufacturing footprint in Europe as sovereign satellite demand becomes a larger part of its growth story. The new Berlin facility adds capacity closer to European customers and could support faster regional execution.
The opportunity comes with a cost. Planet Labs is increasing capital spending while free cash flow has weakened, making utilization and returns on the new capacity important measures of whether the expansion creates durable value.
Planet Labs Adds Major European CapacityPlanet Labs opened its 5,700-square-meter Berlin satellite manufacturing facility in September. The site is designed to scale to as many as 60 satellites annually, with the first satellite expected before year-end.
The expansion also brings production closer to European sovereign customers, where Planet Labs has seen growing interest in satellite services and related capabilities.
PL Is Already Seeing Sovereign DemandIn August, Germany’s Federal Ministry of the Interior awarded Planet Labs a tender for dedicated-capacity satellite services. The award includes options and carries a maximum possible value of €25 million over five years, with Germany becoming the first civil government to procure Planet Labs’ dedicated Constellation Services.
The company is building a broader European presence around that demand. BlackSky Technology Inc. (BKSY - Free Report) , another space-based intelligence provider, is also pursuing international government opportunities through its high-revisit imaging and analytics platform. Satellogic Inc. (SATL - Free Report) serves defense, civil government and commercial customers with persistent Earth-observation monitoring, underscoring the competitive push for sovereign and regional space capabilities.
Planet Labs’ Defense Business Is Expanding FastDefense and Intelligence revenues reached nearly $81 million in the fiscal second quarter of 2027, up 93.3% year over year. The category represented about 70% of quarterly revenues, making it the company’s largest customer vertical during the period.
European demand has been especially strong. Revenues in Europe, the Middle East and Africa increased more than 130% year over year in the quarter. The growth reflects Planet Labs’ expanding sovereign satellite business and gives the Berlin investment a clear regional demand backdrop.
PL Must Fund Capacity Before Returns ImproveThe Berlin buildout is part of a wider investment program. Planet Labs expects fiscal 2027 capital expenditures of $100-$115 million as it expands manufacturing in San Francisco and Berlin, improves supply-chain resiliency and develops next-generation satellite fleets.
Liquidity provides room to invest, with roughly $865 million in cash, cash equivalents and short-term investments at the end of the fiscal second quarter. Still, first-half free cash flow fell to $21.3 million from $54.3 million a year earlier, while trailing 12-month return on invested capital was negative 39.1%. Higher utilization and operating leverage will be important if the new capacity is to improve returns.
PL’s Scores Reflect Opportunity and Execution RiskThe Berlin facility strengthens Planet Labs’ ability to address European sovereign demand, but the investment case still depends on execution. More manufacturing capacity can support growth only if contract wins translate into sustained revenues, improving margins and better capital efficiency.
PL currently carries a Zacks Rank #3 (Hold). It has a Momentum Score of A and Growth Score of B, but a Value Score of F and VGM Score of C. The stronger Momentum and Growth scores point to favorable characteristics in those styles, while the weak Value score argues for valuation discipline. Taken together, the signals support a measured view as investors watch how effectively Planet Labs converts its European expansion into higher-return growth.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Tržby Planet Labs ve 2. čtvrtletí fiskálního roku 2027 vzrostly o 58,1 % na 116,1 mil. USD, ale ocenění na úrovni 8,8násobku očekávaných tržeb zvyšuje nároky na další růst.
Key Takeaways Planet Labs' Q2 revenues surged 58.1% to $116.1M, driven by 93.3% growth in Defense and Intelligence.PL's $815M backlog supports revenue visibility, while fiscal 2027 sales are projected to grow 40-43%.PL trades at 8.8X forward sales, while heavy capital spending and negative returns raise valuation concerns.
Planet Labs PBC (PL - Free Report) combines rapid revenue growth, rising sovereign demand and substantial contracted business with a valuation that already discounts considerable future execution. The setup is attractive on growth, but less forgiving on price.
That leaves investors weighing whether improving operating trends can offset heavy reinvestment needs and weak capital returns. The current evidence supports a measured stance rather than treating growth alone as sufficient reason to become more aggressive.
Planet Labs Has Powerful Revenue MomentumFiscal second-quarter 2027 revenues increased 58.1% year over year to $116.1 million. Defense and Intelligence revenues rose 93.3% to $81 million, making that customer vertical the main driver of the quarter’s expansion.
Management expects fiscal 2027 revenues of $430-$441 million, representing roughly 40-43% annual growth. The outlook also calls for non-GAAP gross margin of 55-57% and adjusted EBITDA profit of $3-$10 million, showing that management expects growth to coexist with improving operating leverage.
PL’s Backlog Adds Visibility to Future GrowthBacklog was approximately $815 million at the end of the fiscal second quarter, up about 11% year over year. Roughly half applies to the next 12 months, while about 70% applies to the next 24 months.
Remaining performance obligations totaled approximately $753 million, up 9%. Management estimates that executing contracts already in backlog could generate more than $400 million in revenues over the next four quarters, excluding new business and renewals, giving PL meaningful near-term visibility.
Planet Labs Still Requires Heavy ReinvestmentPlanet Labs expects fiscal 2027 capital expenditures of $100-$115 million. Management plans to direct spending toward manufacturing expansion, supply-chain resiliency and next-generation satellite fleets as it builds capacity for future demand.
That investment burden is already visible in cash flow. First-half free cash flow fell to $21.3 million from $54.3 million a year earlier, while operating cash flow declined to $68.4 million from $85.1 million. Management still targets positive adjusted free cash flow for the full fiscal year.
PL’s Premium Valuation Raises the BarPL trades at 8.8X forward 12-month sales, above the 2.6X Zacks sub-industry multiple and its 4.8X three-year median. With GAAP operating results still negative and trailing 12-month return on invested capital at negative 39.1%, the current valuation leaves limited room for execution setbacks.
Image Source: Zacks Investment Research
The competitive backdrop also matters. BlackSky Technology Inc. (BKSY - Free Report) provides real-time space-based intelligence using high-revisit imagery, analytics and its proprietary satellite constellation. Satellogic Inc. (SATL - Free Report) is developing its Merlin constellation for daily global monitoring at one-meter resolution, highlighting continued investment across Earth observation.
PL’s Scores Favor Growth but Flag ValuationThe bottom line is that Planet Labs has a credible growth case backed by rapid revenue expansion, a large backlog and increasing sovereign demand, but its valuation and capital intensity argue for patience. Investors may want to see sustained margin progress and better capital efficiency before assigning even more value to future growth.
PL currently carries a Zacks Rank #3 (Hold). It also has a Growth Score of B and Momentum Score of A, while its Value Score of F and VGM Score of C are less supportive. The favorable Growth and Momentum scores recognize stronger characteristics in those styles, but the weak Value score reinforces valuation caution. Taken together with the Hold rank, the signals fit a balanced view rather than a clear buy case.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
SpaceX ve 3. čtvrtletí vykázala záporný volný peněžní tok ve výši 9,9 mld. USD; kapitálové výdaje mají v dalším čtvrtletí vzrůst z 19,5 mld. USD na zhruba 40 mld. USD.
Space Exploration Technologies (SPCX +1.70%) is perhaps the most ambitious company in history. The rocket launch company that just went public in the largest initial public offering (IPO) ever, raising $85.7 billion in the process, is also trying to tackle artificial intelligence (AI) infrastructure, satellite internet, and even semiconductor fabrication.
SpaceX just reported second-quarter earnings, burning $9.9 billion in free cash flow due to its massive capital spending plans. Management has called for even more aggressive spending in the quarters ahead. Here's what that means for SpaceX's AI business, how long its IPO proceeds will last before it needs to raise more funds, and whether the stock is a buy today.
SPCX Space Exploration Technologies$147.21+$2.46 (+1.70%)
NASDAQ · As of 2:19 PM ET 10/23/26
Fast growth, faster capital spending To take advantage of the opportunity afforded by the AI spending boom, SpaceX has built a data center business, along with its own AI software tools, such as its recent acquisition, Cursor, as well as Grok Bot. It has smartly brought on data centers in a supply crunch, leading big customers like Alphabet and Anthropic to flock to it for contracts.
Last quarter, ending in September, SpaceX's AI infrastructure revenue was $7 billion, up from a measly $359 million a year prior, driven by large contracts signed in 2026. However, to achieve this strong revenue growth, SpaceX is incurring heavy capital expenditures, resulting in a negative free cash flow of $9.9 billion for the period.
Total capital expenditures of $19.5 billion in Q3 are expected to double sequentially to around $40 billion, putting SpaceX's capital spending in the same ballpark as hyperscalers like Microsoft. It is going from a standing start at an extremely aggressive pace to try and become a major player in AI infrastructure, and so far, it is paying off with rapid revenue growth.
SpaceX will eventually need to generate positive free cash flow, as the funds from the IPO will run out within two years at the current burn rate. Management should be able to raise funds if this rapid growth continues, but it is always better to bet on a rock-solid business model that generates positive free cash flow than to hope a company can keep raising capital.
Image source: Getty Images.
A complicated story that needs to be woven together SpaceX's business plan is ambitious and will be difficult to execute. That's not to say it hasn't pulled off miracles before, but this time there is a lot on its plate to achieve positive free cash flow within the next few years.
One, the Starship ayloads to orbit. When it does, SpaceX plans to launch a bunch of new advanced satellites for its Starlink internet service, along with orbital data centers for its AI infrastructure business. It is also working on its own semiconductor manufacturing hub in conjunction with Tesla, another technology giant owned by Elon Musk, with which SpaceX is considering a merger.
All this has Elon Musk betting that SpaceX will achieve annual recurring revenue (ARR) of $500 billion to $1 trillion by the end of 2027, which is barely a year from now. Taking its overall quarterly revenue in Q3, its ARR was $58.3 billion. That means around a 10x increase in its quarterly revenue by Q4 of next year, a goal that is likely not achievable in such a short time frame.
SPCX Free Cash Flow (Quarterly) data by YCharts.
Should you buy SpaceX despite its cash burn? Investors are rewarding SpaceX for burning cash to accelerate revenue growth as it invests in AI data centers. It now has a market cap of $2.15 trillion.
Unless you believe Musk's claims that ARR will reach $500 billion or more by this time next year, SpaceX stock is likely overvalued and very risky to buy, given its heavy cash burn. It currently trades at a price-to-sales ratio (P/S) of 69, which is one of the most expensive sales ratios in the stock market today.
Sure, it is one of the fastest-growing businesses, but who's to say when the AI spending boom will slow down? That would be detrimental to SpaceX's share price.
For all these reasons, it is probably best to avoid buying SpaceX stock right now.
Tesla snížila roční výhled kapitálových výdajů o pětinu; její akcie v následující seanci klesly o 3,08 % navzdory upravenému zisku na akcii (EPS) ve výši 0,48 USD, který překonal odhad 0,4511 USD.
A top Wall Street analyst sees Tesla soaring while the rest of the Street keeps slashing estimates and the stock drifts further below its highs. The case for and against that bullish call comes down to one business that Tesla…
Tesla (NASDAQ:TSLA | TSLA Price Prediction) currently trades at $374.58. The average price target among analysts is $397.83, which implies 6.2% upside.
That consensus gap is small. The headline number comes from the top of the range. Wedbush Securities analyst Dan Ives holds a Street-high $600.00 target, which implies about 60.2% upside, a gap well above 40%. Tigress Financial’s Ivan Feinseth is right behind him at $550.00.
Tesla is valued at about $1.48 trillion. That price reflects an AI and robotics company, but most of the revenue still comes from cars. Its latest quarterly report tested which of those two stories investors believe, and the stock gave a mixed answer.
A Spending Cut Turned Tesla’s Earnings Beat Into a Selloff
The main blow was a surprise cut to capital spending. Tesla cut its annual capital expenditure forecast by a fifth, and shares fell 3.08% in the next session. That came even though adjusted EPS of $0.48 beat the $0.4511 estimate. Direxion’s Ryan Lee put the worry simply: “Lower capex suggests less of an ‘all-in’ approach to the AI arms race than one would expect from Elon.”
The details below were weak. Revenue of $28.05B was essentially flat year over year. GAAP operating income fell to $718M from $1.62B as R&D rose to $2.76B. Battery shortages limited deliveries to 486,532 vehicles, even with the largest order backlog in four years. Analysts have also cut their full-year 2026 EPS consensus to $1.7421, down from $2.1306 90 days ago.
The damage is mostly specific to Tesla. The stock sits 24.9% below its 52-week high of $498.83 and trades under its 200-day moving average of $386.94. The broader market, meanwhile, has kept rising.
Wedbush Is Valuing Tesla as an AI Company
Wedbush’s case is that Tesla is turning from an EV maker into an AI/autonomous software monopoly. The data supports parts of that story. Active FSD subscriptions grew to 1.74M from 1.04M a year earlier. Cybercab has joined the unsupervised Robotaxi fleet in Austin, and total unsupervised miles grew 8x quarter over quarter to nearly 2M.
Ives believes that scaled robotaxi fleets and recurring software revenue could create a $2T+ to $3T ecosystem valuation. He also points to Optimus. Production of the humanoid robot has started on high-volume lines in Fremont, and the Semi has entered volume production in Nevada. Tesla has $45.4B in cash to pay for all of it.
Most of Wall Street is less enthusiastic. Holds are the largest group with 21 ratings. Estimate revisions have mostly gone down, with 4 downward full-year EPS revisions over the past 30 days. Wedbush’s target covers 12 months. At a forward P/E near 159x, Tesla needs every one of those milestones to arrive on time (we reverse-engineered what the biggest tech winners looked like early and turned it into a free playbook you can grab here).
Detroit and Rivian Fell Harder but Offer More Upside
Several peers have posted sharp recent declines.
General Motors (NYSE:GM) lost 7.7% in a week to $77.22. Its average target of $101.22 implies 31.1% upside. No analysts rate GM a Sell, and 13 rate it a Buy.
Ford (NYSE:F) dropped 8.85% over the past month to $11.94. Its target of $15.56 implies 30.3% upside, although Holds (12) are the most common rating.
Rivian (NASDAQ:RIVN) is down 38.81% this year at $12.06. Its $19 target implies 57.5% upside, but analyst opinion is split.
Rivian has the largest consensus upside in the group. Tesla has the smallest. Like every target in this group, these are estimates that can change.
Tesla Is Lagging the S&P 500 This Year
Tesla is down 16.71% year to date, while the S&P 500 has gained 12.03%. Over the past year, Tesla has lost 14.67%, even after a 3.35% gain over the past week. Trailing P/E stands near 358x.
Here is how the 44 analysts covering the stock rate it:
Tesla’s 60% Case Depends on Robotaxis Scaling Quickly
Tesla earns a closer look here if robotaxi service expands well beyond Austin, FSD subscriptions keep growing and battery supply improves enough to work through the backlog. But caution makes sense if the spending cut means Tesla is slowing down its AI plans, or if operating margins stay near 4.6%.
Jim Cramer has highlighted a structural risk, reasoning that a SpaceX listing would cost Tesla its scarcity value, and that the stock could “keep drifting lower until they either make more progress in robo taxis or the core business finally turns around”. Talk of a merger between Tesla and SpaceX makes that risk harder to judge.
I lean conservative. The consensus target says Tesla is about fairly priced already. Getting to Wedbush’s 60% upside would require nearly perfect execution while earnings estimates are still falling. Until robotaxi revenue shows up in the earnings report, consensus targets for Rivian and Detroit imply more upside than Tesla’s.
Got $1,000? Before You Buy TSLA, Read ThisIf you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And TSLA wasn't one of them.
They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>
Contact [email protected] for any questions or corrections.
American Airlines issued a warning that airfares are likely to remain elevated even if there's a decline in oil prices after losses the carrier suffered earlier in the year amid surging fuel costs.
The carrier's CFO, Devon May, told the Financial Times that "if fuel comes down, I think airfares probably stay largely where they're at right now."
"If fuel prices go up, we need to generate higher yield, we need to generate higher fares to offset that higher fuel price," May said.
American Airlines on Thursday released its earnings for the third quarter, reporting deeper losses in 2026 and updating its forecast to reflect anticipated losses between $1 and $1.60 a share on an adjusted basis this year. Its July forecast ranged from a loss of 65 cents and a profit of 65 cents.
MAJOR AIRLINES CUT FLIGHTS AS HIGHER JET FUEL PRICES HIT CARRIERS
American Airlines projected deeper losses in 2026 due to the surge in fuel costs. (Kevin Carter/Getty Images)
May told the FT that airlines' ticket prices hadn't fully recovered in real terms since the disruptions caused by the COVID-19 pandemic, saying that the price hikes "ideally should have happened back in 2024, but the industry found itself in an oversupply environment."
"This was the first year that everything came together in a way that we were able to push yields back up to where they were seven years ago in real terms," May told the outlet.
AMERICAN AIRLINES ADDS $1,000 TRUMP ACCOUNT MATCH FOR WORKERS' CHILDREN
American Airlines said it expects higher fuel costs to persist into the fourth quarter. (Daniel Slim/AFP via Getty Images)
The company reported a 19% year-over-year increase in third quarter revenue, which was above the high end of its previous guidance range and was the highest in company history when excluding the years following the pandemic.
However, fuel expenses in the third quarter surged 67.5% compared with the same period a year ago, which translated to $1.9 billion in higher fuel costs based on an average price of $3.85 a gallon.
American also forecast higher fuel prices will continue into the company's fourth quarter, with the carrier expecting to face an average fuel price of about $4.70 a gallon – a figure that would nearly double the price in the fourth quarter of 2025 and increase fuel expenses by $2.8 billion year over year.
AMERICAN AIRLINES BETS BIG ON INTERNATIONAL FLIGHTS WITH 7 NEW ROUTES
Ticker Security Last Change Change % AAL NO DATA AVAILABLE - - - Due to the elevated fuel prices, American said that it expects its network growth to slow in 2027 when compared with 2026 levels.
Higher fuel prices have caused airfares to surge, with the most recent data from the Bureau of Labor Statistics showing that airline fares were up 22.4% compared with a year ago in September.
, /PRNewswire/ -- National securities litigation law firm Hagens Berman alerts investors in Bank of America Corporation (NYSE: BAC) to a securities class action lawsuit filed in federal court against Bank of America and certain senior executives alleging violations of federal securities laws. The firm urges investors with substantial losses to submit their trading information.
Class Period: Aug. 1, 2025 – Oct. 13, 2026
Lead Plaintiff Deadline: Dec. 15, 2026
Visit: www.hbsslaw.com/bac
Contact Email: [email protected]
Direct Firm Phone: 844-916-0895
Case Overview & Summary of Allegations
The securities class action lawsuit alleges that throughout the Class Period, Defendants made false and/or misleading statements and failed to disclose material adverse facts regarding Bank of America's compliance controls and regulatory risk exposure. Specifically, Defendants failed to disclose that:
Deficient AML & BSA Compliance Controls: Bank of America maintained deficient Bank Secrecy Act (BSA) and Anti-Money Laundering (AML) monitoring systems, underresourcing compliance functions in favor of revenue generation.
Underreported Suspicious Transactions: The Bank failed to detect, track, or report over $5 billion in suspicious transactions to the Financial Crimes Enforcement Network (FinCEN), including over $1 billion tied to high-risk illicit finance.
Regulatory & Financial Exposure: As a result of these failures, Bank of America faced immense regulatory enforcement actions and multi-billion-dollar penalties, making its prior statements regarding regulatory compliance, risk management, and internal controls materially false and misleading.
The Disclosure & Market Impact
On October 13, 2026, the U.S. Department of the Treasury, FinCEN, and the Office of the Comptroller of the Currency (OCC) announced landmark enforcement actions requiring Bank of America to pay over $1.2 billion in penalties for widespread BSA/AML failures and backlog issues.
Following this disclosure, Bank of America's stock price fell sharply by over 4.8%, closing at $51.39 per share on October 14, 2026, wiping out billions of dollars in market value and causing substantial damages to shareholders.
What Can BAC Investors Do?
If you purchased Bank of America Corporation (NYSE: BAC) shares during the Class Period (August 1, 2025 – October 13, 2026) and suffered losses, you may move the Court to serve as Lead Plaintiff no later than December 15, 2026. A Lead Plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Submit your losses now
Learn More: Visit www.hbsslaw.com or contact Reed Kathrein at (844) 916-0895 or via email at [email protected].
"We're focused on the apparent disparity between the bank's assurances and the Treasury's revelations," said Reed Kathrein, a Hagens Berman partner.
Whistleblowers: Persons with non-public information regarding Bank of America should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Procter & Gamble zvyšuje dividendu již 70 let po sobě; volné peněžní toky ve fiskálním roce 2026 vzrostly o 8 % na 15,1 mld. USD a pokryly dividendové výplaty ve výši 10,2 mld. USD.
Procter & Gamble (PG -1.97%), one of the world's largest consumer staple companies, has raised its dividend annually for 70 consecutive years. That makes it a Dividend King, an elite company that has raised its payout for at least 50 straight years.
Today, P&G's forward yield of 2.6% might not seem impressive compared to the 10-Year Treasury's 5% yield. But over the past 10 years, P&G delivered a total return of nearly 150% with dividends reinvested. Over the past 30 years, it generated a total return of 1,310%. Let's see why P&G consistently grew and why its resilience will matter during the next market crash.
Image source: Getty Images.
Why is P&G a resilient stock?
Over the past seven decades, the U.S. has experienced ten official recessions. Yet P&G resisted those downturns because it sells essential household and personal care products.
P&G shrunk its portfolio from around 180 brands in 2014 to 65 today. Roughly 20 of those brands -- including Tide, Downy, Dawn, Cascade, Pampers, Luvs, Tampax, Bounty, Charmin, Head & Shoulders, Pantene, Olay, SK-II, Crest, Oral-B, Vicks, Pepto-Bismol, and Gillette -- generate more than $1 billion in annual sales.
$161.26-$3.24 (-1.97%)
NYSE · As of 2:12 PM ET 10/23/26
By streamlining its business and focusing on those higher-growth brands, P&G steadily grew its organic sales and core EPS. But over its past few fiscal years (which ended in July of each calendar year), its top- and bottom-line growth cooled off.
Period
FY 2022
FY 2023
FY 2024
FY 2025
FY 2026
Organic Sales Growth
7%
7%
4%
2%
1%
Core EPS Growth
3%
2%
12%
4%
1%
Data source: P&G. (Fiscal year ends in July of the calendar year)
Like many of its industry peers, P&G attributed that slowdown to inflationary headwinds for consumer spending. It's raised its prices to offset slowing volume, but it still struggled to grow in China and North America as macro headwinds intensified.
However, P&G's free cash flow (FCF) still grew 8% to $15.1 billion in fiscal 2026 and easily covered its $10.2 billion in dividend payments. It spent another $5.0 billion on share buybacks during the year, returning over 100% of its FCF to its investors.
For fiscal 2027, P&G expects its organic sales to rise 1%-3% and its core EPS to grow 0%-3%. It plans to pay out over $10 billion in dividends and spend another $5 billion on buybacks. That stabilization should be driven by additional price hikes, the premiumization of its classic brands (Pampers, Pantene, Tide, and Gain), and its growth in China and Latin America.
At $160, P&G trades at 23 times the midpoint of its core EPS forecast for fiscal 2027. That multiple is a bit high relative to its growth potential, but it could maintain that premium valuation as long as rising rates and yields drive investors toward defensive stocks. It should also easily recover from the next market crash.
Altria sends nearly all of its earnings straight to shareholders, leaving almost nothing in reserve, yet the board just approved another dividend raise. Understanding what keeps that math from falling apart reveals everything about whether the 5.68% yield holds or…
Altria (NYSE:MO | MO Price Prediction) pays out 89.3% of its earnings as dividends. That payout ratio is simple math: dividends per share divided by earnings per share. It’s also the clearest way to see how Altria works today. The stock trades at $76.07, up 38.33% year to date, and yields 5.68%. The payout ratio shows how much of that income depends on a cigarette business that keeps shrinking.
Why This Number Tells You More Than the Headlines
The reported numbers say Altria is still growing. Adjusted diluted EPS rose 2.8% to $1.48 in the second quarter, and 2026 guidance calls for $5.61 to $5.72. The payout ratio shows how much cash remains after the dividend is paid. At 89.3%, the answer is very little. On the July 30 call, CFO Heather Newman said, “Historically, after we have the dividend, we have about $1 billion excess in cash.” That leftover cash has to pay for buybacks, debt maturities, and smoke-free products like on! PLUS and the Horizon heated tobacco joint venture.
Here’s an unusual detail: Altria’s book value per share is -$1.598. For years, Altria has sent more money to shareholders through dividends and buybacks than it kept as earnings. It returned about $8 billion in 2025 alone. That practice wiped out shareholder equity, which stood at -$2.6B in Q2. In plain terms, the company’s balance sheet shows more liabilities than assets. Altria continues to rely on steady cash flow and borrowing, with debt-to-EBITDA at 1.9x.
Where the Ratio Stands After the Latest Raise
The board raised the quarterly dividend to $1.11 from $1.06, a 4.7% increase. The new annualized rate is $4.44. Against 2026 adjusted EPS guidance, that rate works out to about 78% to 79% of adjusted earnings. The higher 89.3% figure shows how much one-time charges, like the $2.2B NJOY impairment in 2025, can eat into the buffer. Management targets mid-single-digit dividend growth through 2028, about the same pace as its 3.5% to 5.5% EPS growth outlook. So the ratio should hold roughly steady rather than fall.
What Bulls and Bears Should Track Next
Bearish: Domestic cigarette shipments fell 3.2% in Q2 after a 10.0% drop in 2025. Marlboro’s retail share slid to 39.5% while discount brands rose to 33.8%. Higher prices are carrying the business, with Marlboro’s retail price up about 7%. If smokers push back on those prices, EPS will miss guidance and the payout ratio will rise.
Bullish: Industry cigarette declines have slowed for the fourth consecutive quarter. on! Retail share rose 0.8 share points from the prior quarter to 8.6%. PLUS now reaches 120,000 stores, and contract-manufactured export volume jumped 54.9%.
Verdict on the 5.68% Yield
The 5.68% yield looks sustainable for now because adjusted earnings still cover it with room to spare. Still, an 89.3% payout ratio means Altria can grow its dividend only as long as Marlboro keeps its pricing power.
Contact [email protected] for any questions or corrections.
Like a losing game of tic-tac-toe, GE Aerospace (GE -1.93%) stock has fallen three days in a row since reporting earnings Tuesday. Today's 2.5% decline (as of 11:40 a.m. ET) brings GE stock to nearly a 9% loss this week.
But why?
Image source: Getty Images.
GE Aerospace Q3 earningsGE Aerospace's news this week wasn't bad. The company reported $2.25 per share in earnings on $13.3 billion in sales, beating analyst forecasts on both the top and bottom lines. Revenue rose 16% year over year as commercial airplane engine sales boomed. Operating profit on those sales soared 30% year over year, hitting $3 billion.
Best of all, GE Aerospace reported 49% growth in new orders, giving it a 1.35 book-to-bill ratio and implying sales and profits are still rising.
$287.89-$5.65 (-1.93%)
NYSE · As of 2:15 PM ET 10/23/26
Wall Street worriesDespite all this good news, Bernstein SocGen Group analyst Douglas Harned just lowered his price target on GE Aerospace stock.
Mind you, the analyst still likes GE stock, says there's "strong demand" for GE engines, and recommends buying it. However, as the Iran war drags on, rising jet fuel prices are weighing on airline profits and threaten to cut short the rally. For this reason, Harned is pulling back on his target for GE stock and lowering it to $376.
I agree with the sentiment, but... I worry that Wall Street isn't worrying enough about this risk.
Consider that, based on GE's latest forecast of $9.1 billion in 2026 free cash flow, the stock currently trades at more than 36 times current-year FCF. Most analysts forecast profits to grow by less than 18% per year over the next five years -- which already looks expensive.
If Bernstein is right about high fuel prices hurting jet engine sales, GE's stock could be even more expensive than it looks. Caveat investor.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GE Aerospace. The Motley Fool has a disclosure policy.
Cincinnati Financial vyplácí čtvrtletní dividendu ve výši 0,94 USD na akcii s dividendovým výnosem 2,11 %; anualizovaná dividenda činí 3,76 USD a meziročně vzrostla o 8 %.
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
Based in Fairfield, Cincinnati Financial (CINF - Free Report) is in the Finance sector, and so far this year, shares have seen a price change of 9.16%. The insurer is currently shelling out a dividend of $0.94 per share, with a dividend yield of 2.11%. This compares to the Insurance - Property and Casualty industry's yield of 0.88% and the S&P 500's yield of 1.33%.
Looking at dividend growth, the company's current annualized dividend of $3.76 is up 8% from last year. Over the last 5 years, Cincinnati Financial has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.39%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Cincinnati Financial's current payout ratio is 39%, meaning it paid out 39% of its trailing 12-month EPS as dividend.
Earnings growth looks solid for CINF for this fiscal year. The Zacks Consensus Estimate for 2026 is $8.44 per share, representing a year-over-year earnings growth rate of 6.16%.
Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. But, not every company offers a quarterly payout.
For instance, it's a rare occurrence when a tech start-up or big growth business offers its shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, CINF presents a compelling investment opportunity; it's not only an attractive dividend play, but the stock also boasts a strong Zacks Rank of #2 (Buy).
Adobe ve třetím fiskálním čtvrtletí zvýšila tržby o 12,9 % na 6,76 mld. USD a její non-GAAP zisk na akcii (EPS) dosáhl 6,13 USD, čímž překonala odhady analytiků.
Adobe keeps beating earnings estimates while the stock keeps sliding, and that contradiction has split Wall Street into two very different camps with very different price targets.
The 24/7 Wall St. price target for Adobe (NASDAQ:ADBE | ADBE Price Prediction) is $298.13 over the next 12 months. That means 16.4% upside from the current $256.13. The stock earns a buy rating with high confidence.
Metric Value Current Price $256.13 Price Target from 24/7 Wall St. $298.13 Upside/Downside 16.4% Recommendation BUY Confidence Level 90% Adobe keeps beating estimates while the stock keeps falling, and that gap defines the valuation debate. Shares trade at a forward P/E of 9, which looks cheap for a business that just raised guidance.
Several turnaround catalysts are already on the calendar: a new CEO takes over December 1, Adobe MAX arrives in November, and AI-first ARR is growing more than 150%.
Record Quarters Have Not Stopped the Slide Adobe is down 26.75% year to date and sits well below its 52-week high of $363.70, though it has climbed off the $190.12 low. Momentum has turned recently, with shares up 8.51% over the past week and 3% over the past month.
In fiscal Q3, revenue came in at $6.76 billion, up 12.9% and ahead of the $6.70 billion consensus. Non-GAAP EPS of $6.13 topped the $6.09 estimate, making it the fifth beat in a row.
Jim Cramer summed up the problem in June: the stock traded at “just 8.5 times” earnings as concerns grew that AI will replace software.
Why Bulls See $328 and Beyond Adobe now has more than 1 billion monthly active users, and Firefly ending ARR grew 40% quarter over quarter. The pending Topaz Labs deal adds AI video enhancement.
Buybacks also help, with about $24.55 billion left on the current authorization. Incoming CEO Anil Chakravarthy sees “a massive opportunity for us to be the agentic software leader.” In our bull case, shares reach $328.71.
What Could Keep Adobe Stuck Investors remain wary. Of the analysts covering Adobe, 23 rate it a hold, and the consensus target is $272.31. Analysts on the Q3 call noted that net new ARR fell 36% to 37%. Management’s explanation is that it deliberately sent users into the freemium model and delayed price increases.
The trade-off is reasonable, but it needs to start showing up as revenue. A CFO exit and the CEO transition add execution risk. In our bear case, the stock sits flat at $256.44.
Adobe Trades at Half the Multiple of Microsoft and Salesforce Microsoft (NASDAQ:MSFT) competes with Acrobat and Express through Copilot. Shares trade at 30 times earnings, supported by 43% Azure growth.
Salesforce (NYSE:CRM) competes with Adobe’s Experience Cloud and is growing more slowly, yet it still trades at 27 times earnings.
Company P/E (TTM) Latest Quarterly Revenue Growth Adobe 14 12.9% Microsoft 30 17.75% Salesforce 27 10.83% Even at our target, Adobe would trade at about 11 times forward earnings. Compared with these peers, the 24/7 Wall St. price target looks conservative.
Discount Outweighs Doubt The 24/7 Wall St. price target of $298.13 comes with a buy rating and high confidence.
Valuation is the key factor: double-digit growth at a single-digit forward multiple. The case gets stronger if MAX and the CEO transition show freemium users turning into paying ARR. It weakens if net new ARR keeps contracting into 2027.
Year Price Target from 24/7 Wall St. 2026 $264.13 2027 $298.13 2028 $333.05 2029 $370.90 2030 $388.35 Adobe is expected to keep executing on its current strategy. Faster AI monetization could push the stock higher, while AI tools from competitors could cut into these numbers.
Contact [email protected] for any questions or corrections.
American Express propustí 5 % z přibližně 77 000 zaměstnanců kvůli automatizaci procesů pomocí AI a zaúčtuje náklady na restrukturalizaci ve výši 336 milionů USD.
American Express is slashing 5% of its workforce as the credit card giant prepares to automate some of its internal processes using AI – the latest tech-driven layoffs to hit the financial sector.
The company on Friday announced a $336 million restructuring charge as part of the layoffs, which will impact thousands of the firm’s roughly 77,000 workers.
Christophe Le Caillec, the firm’s chief financial officer, told CNBC after the firm reported its third-quarter earnings that the reorganization will make American Express “leaner, more agile, and also [able] to prepare for AI.”
American Express CEO Stephen Squeri speaks during an event in New York on Nov. 10, 2022. Bloomberg via Getty Images
“You don’t want to automate processes that are not optimally structured,” he added. “So what we’re doing here is to reduce layers and increase spans of controls, so that we can automate and take advantage of AI in the coming quarters and the coming years.”
Shares of American Express slid 3.8% by about 1 p.m. ET as investors took the layoffs as the latest example of AI’s potential to eliminate jobs.
British lender Barclays on Thursday announced 5,000 planned job cuts in its own AI push.
So far this year through September, AI has been cited in more than 120,000 job cut announcements, according to data from Challenger, Gray & Christmas.
The financial sector and other white-collar professions have been among those most impacted by the new tech.
Despite record-low consumer sentiment readings and stubbornly high inflation, American Express reported a rise in profits as shoppers – especially wealthier ones – have shrugged off sky-high prices and continued to spend.
But during a post-earnings call Friday, CEO Stephen Squeri said the AI push and layoffs were necessary to improve efficiency and prepare for the future.
The company announced planned job cuts that will impact thousands of workers. JHVEPhoto – stock.adobe.com
“We’ve got good momentum, but to accelerate innovation and win over the next few years, we needed to become [a] more agile and efficient organization,” he said.
He added that the company will use AI to personalize customer experiences and offers, but assured investors that American Express is “not going to let assistants run rogue through our system.”
Tech giants have reported a slew of concerning incidents in which AI agents broke out of their restraints or turned off safety systems.
Industry leaders like Anthropic CEO Dario Amodei and OpenAI’s Sam Altman have called for more regulations and a development pause after a researcher last month sounded the alarm over the potential for AI to wipe out the human race.
The credit card giant also reported strong earnings. REUTERS
“We need to protect our customers [and] merchants, and we’re only going to allow agents to access our systems that are either approved through API or MCP channels,” Squeri said, referencing two external security systems.
On Friday, the credit card company reported adjusted earnings per share of $4.68 – beating expectations of $4.48.
Revenue jumped 9% to $20.06 billion, slightly missing estimates of $20.12 billion.
American Express also hiked its full-year earnings forecast to $18.30 to $18.60 a share, up from a previous range of $17.30 to $17.90.
Its sale of the company’s stake in Global Business Travel Group helped boost its earnings prediction, according to Le Caillec.
Welltower by měl ve třetím čtvrtletí vykázat tržby ve výši 3,63 mld. USD, což představuje meziroční nárůst o 35 %, a normalizované FFO ve výši 1,64 USD na akcii, meziročně o 22,4 % více.
Key Takeaways WELL is set to report Q3 results Oct. 26, with year-over-year revenue and normalized FFO growth expected.Senior housing demand and muted new supply may support WELL, while long-term leases aid stable revenues.Q3 revenue is pegged at $3.63 billion, up 35%, and normalized FFO per share at $1.64, up 22.4% Y/Y. Welltower, Inc. (WELL - Free Report) is slated to report third-quarter 2026 results on Oct. 26, after market close. The quarterly results are likely to reflect year-over-year growth in revenues and normalized funds from operations (FFO) per share.
In the last reported quarter, this Toledo, OH-based healthcare real estate investment trust (REIT) witnessed a normalized FFO per share of $1.60, beating the Zacks Consensus Estimate of $1.55. Results reflected a rise in revenues on a year-over-year basis. The total portfolio same-store net operating income (SSNOI) increased year over year, driven by SSNOI growth in the senior housing operating (SHO) portfolio.
Over the preceding four quarters, Welltower’s normalized FFO per share beat the Zacks Consensus Estimate on all occasions, with the average beat being 2.1%. The graph below depicts this surprising history:
Factors at Play for WELLWelltower owns a diversified healthcare real estate portfolio across the major markets in the United States, Canada and the U. K. During the third quarter, the company’s SHO portfolio is likely to have continued to benefit from strong demand driven by the aging U.S. population. This demographic tailwind, coupled with muted new seniors-housing supply, is expected to have provided a favorable operating environment for this portfolio.
Further, Welltower’s long-term leases with its healthcare management companies or operators are anticipated to have led to stable revenue generation, boosting its top line.
The Zacks Consensus Estimate for quarterly total revenues is pegged at $3.63 billion, suggesting an increase of 35% from the prior-year period’s reported number.
We expect WELL to have continued its investment and development activities during the to-be-reported quarter, supported by its solid balance sheet position and capital-recycling efforts.
WELL’s activities during the to-be-reported quarter were adequate to garner analysts’ confidence. The Zacks Consensus Estimate for third-quarter normalized FFO per share has been revised 2 cents upward to $1.64 over the past three months. The figure suggests an increase of 22.4% from the year-ago reported number.
However, high interest expenses are likely to have been a spoilsport for Welltower during the to-be-reported quarter.
What Our Quantitative Model Predicts for WELLOur proven model predicts a likely surprise in terms of FFO per share for Welltower this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is the case here.
Welltower currently has an Earnings ESP of +0.30% and carries a Zacks Rank of 2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Other Stocks That Warrant a LookHere are two stocks from the broader REIT industry — BXP, Inc. (BXP - Free Report) and Ventas (VTR - Free Report) — that you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.
BXP is scheduled to report third-quarter 2026 results on Oct. 27. The company has an Earnings ESP of +0.04% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ventas is slated to report third-quarter 2026 results on Oct. 27. VTR has an Earnings ESP of +0.70% and a Zacks Rank of #3 at present.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Očekává se, že MGM Resorts ve 3. čtvrtletí vykáže EPS ve výši 13 centů, což by znamenalo meziroční pokles o 45,8 %, při tržbách ve výši téměř 4,25 miliardy USD.
Key Takeaways MGM Resorts is set to report Q3 earnings on Oct. 28, with EPS expected to fall 45.8% to 13 cents.Strong group bookings, premium gaming and entertainment events are likely to boost MGM's Las Vegas results.MGM's digital revenues are projected to rise to $207M, while regional revenues may decline to $870M.
MGM Resorts International (MGM - Free Report) is scheduled to report third-quarter 2026 results on Oct. 28, after the closing bell.
MGM’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 24%.
Trend in Estimate Revision of MGMThe Zacks Consensus Estimate for third-quarter earnings per share (EPS) is pegged at 13 cents, indicating a deterioration of 45.8% from 24 cents reported in the year-ago quarter.
For revenues, the consensus mark is pegged at nearly $4.25 billion, suggesting growth of 0.1% from the prior-year quarter’s figure.
Let's look at how things have shaped up in the quarter.
Factors Likely to Shape MGM Resorts’ Quarterly ResultsMGM Resorts' third-quarter performance is likely to have benefited from continued momentum across its Las Vegas Strip Resorts, supported by group and convention bookings, premium gaming demand and an expanded entertainment calendar. Management highlighted a favorable group booking environment entering the quarter, alongside a larger calendar of sports and entertainment events compared with the year-ago period. These factors are expected to have supported casino activity, hotel demand and non-gaming spending.
The company's Las Vegas Strip Resorts are likely to have benefited from the recovery at MGM Grand, supported by renovated room inventory and favorable gaming trends. Continued demand for premium gaming experiences and investments in luxury offerings are expected to have aided performance. Management also highlighted encouraging trends in high-end customer spending, which may have supported gaming revenues and overall profitability in the quarter under review. The Zacks Consensus Estimate for third-quarter Las Vegas Strip revenues is pegged at $1.99 billion, compared with $1.98 billion reported in the prior-year quarter. Segment-adjusted property EBITDA is projected at $582 million, down from $601 million reported in the year-ago quarter.
MGM China's third-quarter performance is likely to have benefited from a recovery in gaming volumes following the temporary disruption caused by the World Cup in June. Continued investments in premium gaming facilities, renovated suites and luxury hospitality offerings are expected to have supported customer engagement and gaming activity. The recently upgraded suites at MGM Cotai and expanded premium gaming areas may also have strengthened the company's competitive position in Macao. However, higher intercompany branding fees may have weighed on segment profitability. MGM China’s adjusted property EBITDA is projected at $254 million, down from $284 million in the prior-year quarter.
Digital operations are likely to have supported revenue growth, driven by the launch of MGM Digital's proprietary sportsbook in Sweden and growing traction for BetMGM-branded offerings internationally. Encouraging trends in first-time deposits, active players and net gaming revenues in Brazil may also have aided performance. The consensus estimate for digital revenues is pegged at $207 million, up from $174 million a year ago.
However, softness in lower-end leisure demand may have weighed on Las Vegas hotel performance. Management acknowledged continued demand challenges at Luxor and Excalibur, despite some stabilization from value-oriented packages. Subdued international visitation, cautious spending among value-conscious consumers and seasonal fluctuations in leisure demand may also have constrained hotel revenues and gaming activity. Regional Operations' performance is likely to have reflected continued benefits from targeted capital investments and premium gaming upgrades. However, the absence of contributions from Northfield Park following its divestiture may have weighed on reported revenues and profitability. The consensus estimate for regional revenues is pegged at $870 million, down from $957 million reported in the prior-year quarter, while adjusted property EBITDA is expected to decline to $253 million from $296 million.
What Our Model Says About MGM StockOur proven model does not conclusively predict an earnings beat for MGM Resorts this time around. The company does not have the right combination of the two key ingredients, a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), to increase the odds of an earnings beat.
MGM’s Earnings ESP: MGM Resorts has an Earnings ESP of -22.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
MGM’s Zacks Rank: The company currently has a Zacks Rank #5 (Strong Sell).
Stocks Poised to Beat on EarningsHere are some stocks from the Zacks Consumer Discretionary sector that investors may consider, as our model shows that these have the right combination of elements to post an earnings beat.
Cinemark Holdings, Inc. (CNK - Free Report) currently has an Earnings ESP of +4.49% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cinemark’s earnings for the to-be-reported quarter are expected to increase 127.5%. CNK reported better-than-expected earnings in the trailing three out of four quarters and missed once, the average miss being negative 11.4%.
Rush Street Interactive, Inc. (RSI - Free Report) currently has an Earnings ESP of +2.44% and a Zacks Rank of 2.
RSI’s earnings for the to-be-reported quarter are expected to increase 55.6%. Rush Street Interactive reported better-than-expected earnings in the trailing two out of four quarters, missed estimates once and reported in line once, with the average surprise being 6.3%.
Marriott Vacations Worldwide Corporation (VAC - Free Report) has an Earnings ESP of +10.02% and a Zacks Rank of 3 at present.
Marriott Vacations is expected to register a 45% increase in earnings for the to-be-reported quarter. VAC reported better-than-expected earnings in the trailing three out of four quarters and missed once, with the average surprise being 1.3%.
Edge cloud is splitting from the GPU crowd in today's trading, and one name is pulling so far ahead of its own sector fund that traders are asking whether a single partnership deal just rewrote the growth story.
Edge delivery is setting the pace in the cloud software rebound, and one specialist is pulling well ahead of the group. Fastly (NASDAQ:FSLY) stock is at $24.18, up 8% in afternoon trading. This gain ranks among the strongest performances in the cloud group.
Sector-wide gains are far smaller, which makes the jump in Fastly stock stand out even more. The First Trust Cloud Computing ETF (NASDAQ:SKYY) is trading at $167.36, up 2%. On the broad-market side, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is at $762.42, down 0.2%. Cloud buyers aren’t getting any help from the overall market.
Meanwhile, Nebius Group (NASDAQ:NBIS | NBIS Price Prediction) stock is at $161.31, up 1%, a gain that trails Fastly stock by a wide margin. CoreWeave (NASDAQ:CRWV) stock is trading at $54.85, down 1%, moving opposite both Fastly stock and the cloud fund. That split puts Nebius and CoreWeave on opposite sides of a rebound that Fastly stock is leading.
Edge Cloud Leads the Software Bounce
Cloud software stocks are rebounding, and Fastly is posting one of the larger gains in the group. The company runs an edge cloud network that delivers and secures web content close to users, with product lines spanning network services, security, compute, and observability. Nebius and CoreWeave sit in a different corner of the market, renting out graphics processor computing capacity to customers running AI workloads.
Earlier this month, Fastly expanded its partnership with Jio Platforms to power the upgraded JioCDN content delivery network across India. Under the arrangement, Fastly’s programmable edge cloud runs on Jio’s 5G and fixed broadband network, which gives the platform a carrier-scale distribution path. Any link between that agreement and the stock’s jump is still an open question, since the deal came before the current session.
GPU Cloud Names Split From Fastly
Fastly stock is far outpacing the cloud computing fund, and its lead over the GPU providers is wider still, which keeps the spotlight on Fastly’s edge business, a model tied to how much web traffic flows across its network.
Edge positioning gives Fastly a direct line to the rise in machine-generated traffic, a corner of the market where GPU rental plays no part. Company disclosures describe AI traffic as reshaping the internet and lifting demand for tools such as bot management and distributed denial-of-service protection. Reddit, Universal Music Group, and SeatGeek are among the brands already running on Fastly’s platform.
Optimists see that shift in traffic turning into wider adoption of Fastly’s security and compute products, but skeptics counter that a sharp one-session jump can fade quickly when the broad market is slipping and the stock has already outrun its sector fund. Steady demand for AI computing capacity supports the optimism. For Nebius and CoreWeave, the heavy spending needed for that expansion keeps a lid on it (we covered seven suppliers riding that same AI expansion, from power to networking, in a free report).
Jio Deal Sets Up Fastly’s Next Report
Fastly’s upcoming quarterly report will show whether the expanded Jio partnership shows up. Shareholders can watch for whether management puts specific figures behind the JioCDN launch and the India traffic it carries. Hard evidence of that contribution is what would turn a sharp rally into a story grounded in results.
Running this far ahead of both the SKYY cloud fund and the SPY ETF leaves Fastly stock with little buffer if the cloud rebound cools off. Traders may prefer to keep their exposure small until Fastly’s next quarterly report is released.
Got $1,000? Before You Buy NBIS, Read ThisIf you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And NBIS wasn't one of them.
They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>
Contact [email protected] for any questions or corrections.
General Mills v 1. čtvrtletí fiskálního roku 2027 překonal odhady analytiků: upravený zisk činil 75 centů na akcii a tržby dosáhly 4 389,5 milionu USD, přesto meziročně klesly.
A month has gone by since the last earnings report for General Mills (GIS - Free Report) . Shares have added about 1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is General Mills due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
General Mills Q1 Earnings Beat Estimates on Pricing and Mix BenefitsGeneral Mills reported first-quarter fiscal 2027 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. However, both metrics declined year over year. The company posted adjusted earnings of 75 cents per share, down 13% year over year in constant currency but above the Zacks Consensus Estimate of 72 cents. Quarterly profitability was pressured by higher input costs and lower volume, partly offset by favorable net price realization and mix.
Net sales declined 3% year over year to $4,389.5 million, but topped the consensus estimate of $4,344 million. Organic net sales were essentially flat from the prior-year period. Adjusted gross margin contracted 90 basis points to 33.3% of net sales. Higher input costs drove the decline, while favorable net price realization and mix provided a partial offset. We expected an adjusted gross margin of 33.8%.
Adjusted operating profit fell 11% in constant currency to $634 million, and adjusted operating margin declined 130 basis points to 14.4%. We expected an adjusted operating margin of 14.3% for the quarter.
Decoding GIS’ Segmental PerformanceNorth America Retail sales declined 7% year over year to $2,451.8 million, including a 4-point headwind from the U.S. yogurt divestiture. Sales fell at a double-digit rate in Big G Cereal & Canada, including the divestiture impact, declined at a mid-single-digit rate in U.S. Snacks and were flat in U.S. Meals & Baking Solutions. Organic net sales decreased 3% and trailed Nielsen-measured retail sales by about 1 point due to changes in retailer inventory. Retail sales growth improved sequentially by 2 points, while dollar-share trends strengthened across most priority categories.
North America Pet sales were essentially flat at $612.8 million. Cat food sales increased at a double-digit rate and pet treats grew at a low-single-digit rate, while dog food sales declined at a high-single-digit rate. Organic net sales were flat and exceeded all-channel retail sales growth by about 1 point, aided by an extra month of Whitebridge Pet Brands results following the alignment of its calendar with General Mills' August fiscal quarter end.
North America Foodservice sales increased 1% to $523.1 million despite a 2-point headwind from the U.S. yogurt divestiture. Organic net sales advanced 4%, led by growth in cereal and frozen meals. The segment held or gained market share across all of its priority businesses.
International sales grew 4% to $794.3 million, including a 1-point benefit from foreign currency exchange. Organic net sales also increased 4%, driven by growth in distributor markets, India and China.
GIS Reaffirms Fiscal 2027 OutlookGeneral Mills reaffirmed fiscal 2027 organic net sales growth of down 1.5% to up 0.5%. Adjusted operating profit is expected to be down 8-13% in constant currency, while adjusted earnings are projected at $3-$3.20 per share. Free cash flow conversion is expected to be approximately 95% of adjusted after-tax earnings.
The company continues to target at least $750 million of savings from Holistic Margin Management, its global transformation initiative and other cost actions. It also expects roughly 9 points of operating-profit headwind and 11 points of earnings-per-share headwind from lapping the 53rd week, normalizing incentive expense and fiscal 2026 divestitures. The net impact of divestitures, foreign exchange and the 53rd week is expected to reduce reported sales growth by about 4%.
How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.
VGM ScoresAt this time, General Mills has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, General Mills has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Gilead Sciences uzavřela s Texasem mimosoudní vyrovnání ve výši 45 milionů USD kvůli tvrzením, že nelegálními pobídkami ovlivňovala lékaře k předepisování svých léků, čímž zatěžovala program Medicaid.
Litigation sought reimbursements for violations of state law in prescribing practices, charges to Medicaid program
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications.
In many cases, these prescriptions resulted in millions of dollars in claims submitted to Texas Medicaid in violation of the Texas Health Care Program Fraud Prevention Act. As outlined in the lawsuit, Gilead allegedly offered other incentives such as “free nurses” and reimbursement support services to further influence medical providers to prescribe the company’s products.
In the litigation initially filed in 2023, the firm’s Mark Lanier, Zeke DeRose, Jonathan Wilkerson and Alex Brown represented Health Choice Advocates, whose mission is to investigate and bring Medicaid fraud litigation against major pharmaceutical companies. Attorneys with the firm of McKool Smith PC served as co-counsel for the non-profit company.
“As we’ve seen in many other cases, Big Pharma is often motivated by corporate profits rather than what is best and safest for patients, and what is in compliance with the law,” says Mr. Lanier. “We are proud to stand with the State of Texas in exposing this kickback scheme and prevent further abuse of taxpayer funds and the Medicaid program.”
The firm is also supporting ongoing and separate litigation brought by the Attorney General against Bristol-Myers Squibb Co., Novartis and Eli Lilly and Company for similar claims of unlawful prescribing practices and fraud.
About the Lanier Law Firm
For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 60 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, Fort Worth and Los Angeles. To learn more, visit http://www.lanierlawfirm.com.
Palantir trades near all-time highs while Wall Street sees almost no room left to run, yet one number looming on the 2027 horizon suggests analysts may be thinking far too small.
Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has grown into the operating system that both the Pentagon and corporate America use for AI. Gotham handles government work, Foundry runs commercial data, and AIP turns large language models into working agents.
Chief executive Alex Karp summed up the second quarter this way: “Demand for AI sovereignty has now been unleashed.”
The stock is up 12.17% year to date at $199.38. It has climbed 87% from its 52-week low of $106.37. The number I’m watching for 2027 is $300, and several catalysts could get Palantir there.
Wall Street Sees Little Upside, but Estimates Keep Rising
The consensus price target is $206.43, which implies only 3.5% upside. Analysts are split, with 19 Buy ratings against 9 Holds. Valuation explains the caution better than the fundamentals do.
For 2027, analysts expect revenue of $12.33 billion, up 50%. They see EPS of $2.3505, up 45%. Ninety days ago, the 2027 EPS forecast was $2.0945, so it has risen 12% since then.
Here’s the Math Behind a $300 Palantir
Today Palantir trades at about 85x estimated 2027 earnings. At $300, that multiple would rise to roughly 128x. That’s steep, but Palantir’s Rule of 40 score is 155% and its adjusted operating margin is 62%.
Few software companies have combined growth and profitability at this level. If 2027 earnings come in above forecasts, the multiple needed at $300 shrinks.
How might Palantir reach $300?
A long beat streak: Palantir has topped estimates for 10 straight quarters. In Q2, EPS of $0.41 beat the estimate by 46.43%.
Karp’s stretch goal: Karp said he is “driving the business to grow at a rate equal or above to what we have in U.S. commercial for the next 18 months.” U.S. commercial revenue grew 149% in Q2.
Backlog: Remaining deal value reached $13.1 billion, up 83%. Net dollar retention hit 157%.
Defense spending: The FY2027 Department of War budget request includes $46 billion for a sovereign AI toolkit. It also sets aside $2.3 billion for the Maven Smart System, a program Palantir already supports.
Palantir’s History Says 50% Gains Are Within Reach
Reaching $300 requires a gain of about 50%. Palantir has passed that bar several times. Shares rose 167% in 2023, 340% in 2024, and 135% in 2025.
Volatility cuts both ways, though. In 2022, the stock fell 65%. Its beta of 1.602 means a market pullback would hit Palantir harder than most stocks.
$300 Is a Stretch, but Here’s Why It’s Possible
Removing $300 means a gain of about 50%, far above what Wall Street’s target implies. Even so, the business is speeding up. Full-year 2026 revenue guidance calls for 82% growth, estimates are still climbing, and Palantir keeps beating them.
The main risks are the stock’s high valuation and its heavy reliance on U.S. customers. If AIP keeps converting pilot programs into large contracts and defense AI budgets come through, $300 is a reachable goal.
The traits that showed up early in past monster tech runs are the ones we cataloged in a free playbook on spotting the next Nvidia. Returns like this come unevenly from year to year, and this is the path for Palantir to post another outsized gain in 2027.
Contact [email protected] for any questions or corrections.
Every AI chip, every smartphone processor, and every data center upgrade has to pass through the same tollbooth. Here is why one investor keeps buying that tollbooth without apology, and why the geopolitical risk around it changes the math less…
Every time I have extra cash, I buy more Taiwan Semiconductor Manufacturing (NYSE:TSM | TSM Price Prediction). I have stopped apologizing for it. My thesis fits in one sentence. Within five years, TSMC will work like a utility for global computing: a toll road that AI accelerators, smartphone processors and data center chips have to use, and it pays shareholders for every trip.
Why Every AI Player Pays the Toll On the third-quarter call, management said it plainly: “all the AI players are working with TSMC.” Chips at 7nm and below made up 79% of wafer revenue. Production at 2nm grew from 3% of wafer revenue in Q2 to 8% in Q3. High-performance computing now brings in 68% of revenue. The company also says “demand is still far above our capability to supply today.” I look for exactly that in a utility: a broad customer base (534 customers and 12,682 products in 2025) that keeps asking for more capacity than the company can build.
Receipts Behind My Buying Start with growth. Third-quarter revenue reached $46.72 billion, up 41.2% YoY in USD terms. Management raised its full-year 2026 outlook to around 44% growth. Its Q4 guidance of $52.3 billion to $54.3 billion works out to 58% year-over-year growth at the midpoint.
Next comes profitability. Gross margin came in at 66.4%, operating margin at 58.7% and ROE at 45.5%. EPS per ADR of $4.60 beat the $4.46 consensus.
Then there is income. The quarter produced $14.90 billion in free cash flow, and the company holds $126 billion in cash and marketable securities. The quarterly dividend rose from NT$6.00 to NT$7.00, and management says it is committed to a “sustainable and steadily increasing cash dividend per share.” Over the past ten years, the shares have returned 1543.82%.
Why My Money Skips Intel and GlobalFoundries There’s real momentum at Intel (NASDAQ:INTC). Even so, its foundry unit posted a $2.1 billion quarterly operating loss, its Q2 GAAP net loss came to $11.03 billion (mostly from a non-cash charge), and its dividend yield is 0. For a retirement account, I want income today. Specialty processes are the focus at GlobalFoundries (NASDAQ:GFS). Its Q2 revenue grew 5.81% at a 28.3% gross margin. TSMC’s margins and growth rate are both far higher.
Risk I Refuse to Ignore Taiwan is the risk that could hurt this position. European auditors call cross-strait tensions “a source of persistent insecurity” for the chip sector. Building overseas also costs money. Margin dilution from overseas fabs should increase from about 2% to 3%-4%, and 2026 capex runs $60 billion to $64 billion. The stock has fallen 8.77% over the past month.
TSMC’s expanding presence keeps the thesis intact. The second Arizona fab starts volume production in Q3 2027, and Japan gets 3nm in 2028. Those overseas costs buy geographic resilience, and I am willing to pay for that.
What Keeps My Buy Button Active N2 capacity should more than double in 2027. A14 volume production begins in 2028, and management expects it to become a bigger node. Its position is clear: “We have no intention of leaving any food on the table for others.” I plan to keep collecting the toll alongside TSMC for decades.
Contact [email protected] for any questions or corrections.
Guggenheim zvýšil cílovou cenu pro ServiceNow z původních 125 USD na 175 USD a ponechal doporučení „koupit“. Odkázal přitom na stabilní poptávku a potenciál překonat čtvrtletní očekávání.
Guggenheim Just Raised Its ServiceNow Price Target by 40% as AI Demand Builds Summary
Guggenheim raised its ServiceNow price target to $175, citing steady customer demand and the potential for the software company to beat quarterly expectations
ServiceNow (NOW) received a higher valuation assessment from Guggenheim, which raised its price target to $175 from $125 and retained a Buy rating. The new objective relies on a valuation of roughly 10.5 times projected recurring revenue.
Feedback from five partners suggests customers are continuing to spend on ServiceNow's software, although demand has not broadly accelerated. One partner described business as better than anticipated, while four reported performance close to their expectations. Guggenheim believes this environment supports the company's prospects for meeting third-quarter estimates for growth in contracted work awaiting revenue recognition.
The brokerage also sees the company's core IT service-management business supporting sales momentum. Its partners reported healthy pipelines, while Guggenheim expects management's guidance for the following quarter to be at least in line with market forecasts.
ServiceNow's strategy of incorporating artificial intelligence features into product packages has received differing reactions. Some partners observed increased usage and said customers were finding it easier to assess potential returns. Others said the new pricing structure had caused dissatisfaction among buyers. Overall adoption of AI offerings remains at an early stage, though two partners reported growing interest in AI Control Tower.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Bank of America před zveřejněním výsledků za třetí čtvrtletí zvýšila cílovou cenu akcií ServiceNow ze 150 USD na 180 USD a ponechala doporučení „koupit“.
ServiceNow Inc. (NYSE:NOW) received a bullish endorsement from Bank of America on Friday, as the firm raised its price forecast ahead of the software company’s third-quarter earnings report.
Bank of America analyst Tal Liani maintained a Buy rating and raised the price forecast to $180 from $150.
The analyst expects rising demand for artificial intelligence-powered business automation to support ServiceNow’s revenue growth and customer spending.
AI Adoption Could Drive Next Wave of GrowthLiani believes ServiceNow is well positioned to benefit as businesses move beyond basic AI automation toward more complex workflows.
The company’s established workflow platform, customer relationships and enterprise data infrastructure could give it an advantage over competing AI providers.
ServiceNow’s AI Control Tower, AI-native products and new AI Specialists could also drive adoption across IT, customer relationship management, employee services and cybersecurity.
Bank of America sees a cost advantage for ServiceNow because its platform already contains much of the data needed to deploy AI agents.
Competing providers may face additional expenses to extract, organize and reintegrate enterprise data.
The firm raised its valuation multiple to 27 times estimated 2027 enterprise value to free cash flow from 23 times, reflecting expectations for broader AI adoption and additional customer spending.
Corporate Spending Survey Supports Bullish OutlookBank of America’s October survey of chief information officers showed sustained demand for IT services and growing interest in AI.
The survey found that 42% of respondents ranked IT service management and IT operations management among their five biggest spending priorities.
Meanwhile, 54.5% said they were likely or very likely to use ServiceNow for back-office AI applications.
About 36% of respondents expected AI to account for more than 10% of their software budgets.
However, broader software spending growth could remain modest. About 31% of respondents expected budget increases of 1% to 5% in 2027, while 27% anticipated growth of 6% to 10%.
The findings suggest ServiceNow could benefit from both its established enterprise software business and rising corporate investment in AI.
ServiceNow Earnings: Wall Street Expects Revenue GrowthServiceNow confirmed that it will report third-quarter financial results after the market closes Wednesday, Oct. 28.
Wall Street expects earnings of $1.03 per share, up from 96 cents a year earlier. Revenue is expected to rise to $4.09 billion from $3.41 billion in the year-ago quarter.
Bank of America projects subscription revenue growth of 20.6% year over year to approximately $3.98 billion, including 18.5% organic growth.
The firm also expects current remaining performance obligations, a measure of contracted revenue expected to be recognized over the next 12 months, to grow 20% in constant currency.
Investors will closely watch ServiceNow’s progress toward its $1.5 billion annual contract value goal for AI products in fiscal 2026.
Bank of America expects some pressure on gross margins, although operating efficiencies could help offset the impact. The firm forecasts a third-quarter operating margin of 31.1%.
Wall Street Analysts Turn More BullishServiceNow carries an average analyst price forecast of $158.72, with a Buy consensus rating.
Several Wall Street firms have recently raised their forecasts ahead of the company’s earnings announcement.
On Friday, Guggenheim maintained its Buy rating and raised its price forecast to $175.
Truist Securities maintained a Buy rating and lifted its forecast to $180 on Wednesday, Oct. 21.
StoneX also maintained a Buy rating and raised its forecast to $165 on Monday, Oct. 19.
The upgrades reflect growing analyst optimism about ServiceNow’s AI opportunities and enterprise software demand.
Premium Valuation Remains a RiskDespite the bullish outlook, ServiceNow trades at a price-to-earnings ratio of 98.1, reflecting a premium valuation.
Bank of America warned that the stock could face pressure if bookings disappoint or investor sentiment weakens.
The firm also highlighted competition, slower enterprise software spending and rising AI infrastructure costs as potential risks.
Additionally, customers may increasingly expect AI capabilities to be included in existing subscriptions rather than purchased separately, potentially limiting revenue opportunities.
Still, Bank of America believes ServiceNow’s enterprise relationships, established workflow platform and expanding AI capabilities position the company to capture a larger share of corporate technology spending.
NOW Price Action: ServiceNow shares were down 0.13% at $156.05 at the time of publication on Friday, according to Benzinga Pro data.
Peněženky ETF společnosti BlackRock převedly na Coinbase Prime 3 215 BTC v hodnotě 262,4 milionu USD, což zřejmě odpovídá již oznámenému odlivu 254,1 milionu USD z IBIT.
A massive crypto transfer from BlackRock's ETF wallets to Coinbase Prime set off alarm bells across crypto markets, but the real question is whether on-chain traders are misreading the signal entirely.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Wallets tied to BlackRock’s (NYSE: BLK) spot ETFs moved 3,215 BTC, valued at $262.4 million, to Coinbase Prime, according to on-chain records from October 23, 2026. Coinbase Prime, Coinbase’s institutional trading desk (NASDAQ: COIN), also received another 38,882 ETH, worth $93.2 million, from those wallets. This brings the total transfer to about $355.6 million in just two hours.
The timing is concerning. On October 22, spot Bitcoin ETFs faced $635.6 million in net outflows, and Bitcoin (CRYPTO: BTC) dropped by 3.3% to $81,429. Crypto enthusiasts often interpret such large transfers to exchanges as a sign of significant selling ahead.
However, despite these transfers, Bitcoin trades at $81,858 as of October 23, up 0.3% over the past 24 hours, while Ethereum (CRYPTO: ETH) remains nearly unchanged near $2,408. This raises the question: does this transfer signal a fresh wave of selling, or is it just a paper trail for sales that already occurred?
What BlackRock’s $262 Million Coinbase Transfer Reveals
An on-chain transfer represents the movement of coins between two wallets, publicly recorded on the blockchain. Analytics firms label these wallets to help readers identify where the coins came from and where they’re going. A common trading principle is that when coins flow onto an exchange, traders can sell them, which can read as bearish. Conversely, coins moving off exchanges suggest long-term holding.
Coinbase Prime acts as a prime broker, holding, trading, and settling assets for major institutions through a single account. Because Coinbase is BlackRock’s primary custody and trading partner for its crypto funds, BlackRock moves coins between Coinbase-run wallets as standard fund-management practice.
Interestingly, this transfer aligns closely with an outflow from one of BlackRock’s funds. The $262.4 million in Bitcoin moved corresponds to the $254.1 million that exited the iShares Bitcoin Trust (NASDAQ: IBIT) on October 22, according to SoSoValue.
Why the Coinbase Prime Transfer Is Less Alarming Than It Looks
Most iShares Bitcoin Trust trades do not directly move Bitcoin. When an investor sells IBIT shares on the stock market, another investor buys them, and the fund’s coins remain intact. Coins transfer only when an Authorized Participant, such as a large bank or trading firm, redeems shares with the fund.
BlackRock’s iShares prospectus explains this clearly. In a redemption scenario, “an Authorized Participant deposits Creation Units with a Fund and receives from the Fund a redemption basket,” which can consist of assets or “a specified amount of cash.”
In a cash redemption, the fund sells Bitcoin to raise money through its prime broker, while in an in-kind redemption, the Authorized Participant receives the actual Bitcoin and may choose to hold, hedge, or sell them. In both instances, this recent transfer settles orders investors placed on October 22, already reflected in the published flow numbers. A trader interpreting the wallet movement as new selling could mistakenly count the same $254.1 million twice.
The Ethereum transfer follows the same logic, indicating redemptions from BlackRock’s Ethereum ETF, which is managed through the same account. Furthermore, the outflows are not solely attributable to BlackRock. The Fidelity Wise Origin Bitcoin Fund witnessed $217.5 million in outflows, the ARK 21Shares Bitcoin ETF had $109.4 million, and Grayscale’s and Bitwise’s funds saw outflows of $29.5 million and $27.4 million, respectively. However, BlackRock’s movements drew more attention because of greater scrutiny.
What Could Change the Direction of Bitcoin’s ETF Flows
Bitcoin’s price is closely linked with ETF flows, and October 22 marked a break in buying momentum. The funds had previously attracted $1.08 billion over the three preceding sessions, so after October 22’s outflow, they still brought in a net $442.7 million from October 19 to 22.
IBIT’s activity fueled much of this, drawing in $665.2 million on October 19 and $235 million on October 21. Overall, total net inflows across all spot Bitcoin ETFs stood at $57.32 billion as of October 22.
The funds have experienced other days of outflows this month that did not lead to a downward trend. On October 7, they posted $487.1 million in outflows, and on October 14, $261.5 million, but inflows followed both instances.
Bitcoin’s price has followed a similar pattern, down 0.3% over the past week, 3.7% over the month, and 7.2% year to date. Nevertheless, it remains up 26.3% over the past 90 days, suggesting buyers have maintained a rebound from summer lows. As of the morning of October 23, flow data had not yet been published, which could provide investors with clearer insights than any wallet alert.
Is More Bitcoin Selling Coming After BlackRock’s Transfer?
The transfer to Coinbase Prime appears to record transactions that have already occurred, closely matching the size of redemptions reported on October 22. This transfer alone does not suggest more sellers are queuing up, implying significant additional selling may not be on the horizon yet.
Two checks could change that view. Another outflow near October 22’s $635.6 million, or outflows that wipe out the $442.7 million net inflow from October 19 to 22, would point to wider selling. On price, a close below $81,429 would suggest buyers cannot absorb the redemptions, while a move above $84,378, its September 23 level, would show buyers back in control.
Contact [email protected] for any questions or corrections.
Coinbase umožňuje nástrojům AI, jako jsou ChatGPT, Claude a Grok, obchodovat jménem zákazníků; uživatelé mohou omezit přístup k portfoliím, kontrolovat příkazy a agenta kdykoli odpojit.
Coinbase now lets ChatGPT, Claude, and Grok place real trades in your crypto account, and the safeguards put most of the risk squarely on you. Here is what users and investors need to understand before connecting an AI to their…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Coinbase (NASDAQ: COIN | COIN Price Prediction) recently announced that it now lets AI agents trade within customer accounts. On October 22, 2026, the company shared on X that “Coinbase is open for AI agents.” This new feature lets users connect AI tools like ChatGPT, Claude, Grok, and Muse to trade cryptocurrencies, stocks, and derivatives from a single conversation on its Everything Exchange.
Despite this exciting development, the market reaction was muted. COIN shares closed around $169, down 4.5% on October 22 after a 5% gain the previous day on news of new GENIUS Act regulations. Most of the decline occurred before the announcement near the end of the trading day. Shares were held at approximately $169 earlier.
Coinbase Users Can Start Using AI Agents Right Away
The new feature is live, and Coinbase lets users choose which portfolios the AI agent can access, preview orders before they execute, and disconnect the agent at any time.
The connection process utilizes Coinbase’s MCP server—short for model context protocol—a standard method for AI assistants to integrate with applications. For example, in ChatGPT, a user can add the URL agents.coinbase.com/mcp as a custom server, log in to Coinbase, and choose which portfolios the agent can access through an approval screen.
Coinbase has approved several AI assistants for this feature, including ChatGPT, Grok, Grok Bot, Muse, Perplexity Computer, Claude, Claude Code, and Codex CLI. A September 2026 update also added support for U.S. stocks and ETFs, as well as x402 payments, enabling agents to buy market data using a user’s USD Coin (CRYPTO: USDC) balance. However, Coinbase has not provided specific details on fees, user counts, or revenue goals for this feature.
AI Agents Could Lift Coinbase’s Trading Fees, but Not Yet
In the short term, the impact on Coinbase’s bottom line appears minimal. The company reported Q2 2026 revenue of $1.22 billion, down 18.5% from the previous year, along with a GAAP loss of $1.36 per share. Revenue from consumer transactions—essentially the fees paid by retail traders—fell 20% to $452 million.
During the July 30 earnings call, Coinbase CEO Brian Armstrong said agentic finance is still in its early stages and that the company doesn’t have specific forecasts to share. While increased trading by AI agents could raise consumer fees in the future, especially during a broader crypto rebound, Coinbase has not yet reported any revenue from these agents.
Coinbase’s Safeguards Still Leave Users With Most of the Risk
The biggest risk users face is misunderstanding the instructions. For instance, if a user requests “a little crypto,” the AI must interpret what “a little” means, leaving the user accountable for the trade. Another risk is prompt injection, where hidden text could mislead an agent into acting against the owner’s wishes. Additionally, rogue agent tools could compromise Coinbase logins, and overly broad permissions can exacerbate these vulnerabilities.
Coinbase advises users to create a separate portfolio for AI trading, fund it only with money they can afford to lose, and restrict the agent’s access to that account. This approach helps contain any potential losses. Unlike Telegram trading bots, Coinbase keeps funds in a regulated exchange account and offers order previews and an off switch for safety.
Furthermore, Armstrong has expressed confidence that agents will select reliable, safe, and compliant infrastructure, favoring Coinbase’s offerings. The platform reportedly handles more than 99% of stablecoin volume for agentic transactions on Base, its blockchain network, which reinforces its leading position.
Do Coinbase AI Agents Change Anything for COIN Holders? Currently, we believe the introduction of AI trading features won’t change much for COIN holders. While the new feature is beneficial and includes adequate safety measures, the market’s disinterest seems justified, especially since Coinbase hasn’t tied it to revenue. Users may mainly face risk from a bad trade or a compromised agent, but keeping a small, separate portfolio can limit losses.
The real cost for COIN shareholders may simply be the waiting game. Our perspective could shift if Coinbase’s Q3 2026 earnings report reveals meaningful data on agent trading volume or revenue. Until then, a rise back above $177—the October 21 closing price, about a 5% increase from current levels—could signal that investors are beginning to value this new feature.
Contact [email protected] for any questions or corrections.
Key Takeaways Ventas is set to report Q3 2026 results Oct. 27, with revenues seen rising 18.3% and FFO per share 11.4%.Senior housing occupancy and long-term leases are expected to support rental revenues and quarterly growth.Triple-net rental income is projected to fall to $125.2M, while high interest expenses may weigh on results. Ventas, Inc. (VTR - Free Report) is scheduled to report third-quarter 2026 results on Oct. 27, after market close. The quarterly results are likely to show year-over-year growth in revenues and normalized funds from operations (FFO) per share.
In the last reported quarter, this Chicago-based healthcare real estate investment trust (REIT) delivered a normalized FFO per share of 97 cents, beating the Zacks Consensus Estimate by a cent. The quarterly results reflected a year-over-year increase in same-store cash net operating income, driven by strong performance in the senior housing operating portfolio (SHOP) and outpatient medical research (OM&R) portfolio.
Ventas’ normalized FFO per share surpassed the Zacks Consensus Estimate in three of the preceding four quarters and met once, with the average beat being 1.37%. The graph below depicts this surprising history:
Factors at Play for VTRIn the third quarter of 2026, Ventas’ SHOP is likely to have benefited from an aging U.S. population and a rise in healthcare expenditure by this age cohort, which is generally higher than that of the average population. With the segment witnessing positive net move-ins, occupancy is expected to have remained high.
A well-diversified tenant base with long-term leases is expected to have contributed well to stable rental revenue generation, boosting the top line.
However, the triple-net leased properties are likely to have been affected during the to-be-reported quarter. Further, high interest expenses are expected to have cast a pall on the company’s performance to some extent.
VTR’s Q3 ProjectionsThe Zacks Consensus Estimate for third-quarter 2026 revenues is currently pegged at $1.76 billion, implying an 18.3% increase from the prior-year quarter’s reported figure.
The Zacks Consensus Estimate for third-quarter resident fees and services is pegged at $1.39 billion, suggesting an increase from $1.09 billion reported in the year-ago period.
The consensus mark for OM&R portfolio rental income for the third quarter is pegged at $229.5 million, indicating an increase from $226.2 million reported in the year-ago period.
However, the Zacks Consensus Estimate for third-quarter triple-net leased properties' rental income is pegged at $125.2 million, suggesting a decrease from $160.1 million reported in the year-ago period.
Ventas’ activities during the soon-to-be-reported quarter have been inadequate to gain analysts’ confidence. The Zacks Consensus Estimate for third-quarter FFO per share has decreased a cent to 98 cents over the past week. However, the figure implies an increase of 11.4% from the year-ago quarter’s reported number.
What Our Quantitative Model Predicts for VTROur proven model predicts a likely surprise in terms of FFO per share for Ventas this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is the case here.
Ventas currently has an Earnings ESP of +0.70% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks That Warrant a LookHere are two stocks from the broader REIT industry — BXP, Inc. (BXP - Free Report) and American Healthcare REIT (AHR - Free Report) — that you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.
BXP, which is scheduled to report third-quarter 2026 results on Oct. 27, has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.
American Healthcare REIT is slated to report third-quarter 2026 results on Nov. 5. AHR has an Earnings ESP of +0.60% and a Zacks Rank of #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Jefferies ponechala doporučení pro Fortinet (FTNT) na stupni „držet“. Klíčový bude výhled pro rok 2027, protože tržní konsenzus očekává růst tržeb z produktů jen o 9 %.
Jefferies has maintained a 'hold' rating on Fortinet Inc (NASDAQ:FTNT) arguing that its next earnings outlook will matter more than another strong quarter as investors assess whether product growth can endure into financial year 2027.
The broker expects product revenue growth of around 50% year on year in the third quarter, well above the 31% consensus forecast, supported by positive industry checks, pricing increases and accelerated firewall replacement activity.
However, Jefferies believes the fourth-quarter guidance and any initial framework for 2027 will be more important, as investors remain wary of a potential slowdown following several quarters of strong growth.
A survey of value-added resellers (VARs), which sell and support cybersecurity products, found the US cybersecurity company's average performance was 2.5% above plan, up from 2.3% in the previous quarter and ahead of the survey average of 1.5%.
The survey also found that 54% of respondents had observed customers bringing forward firewall purchases, supporting the broker's view that replacement demand could sustain momentum for another two to three quarters.
Jefferies expects fourth-quarter product revenue guidance to exceed the current consensus forecast of $772 million, representing annual growth of 11.7%, while leaving room for further outperformance.
The broker noted that the consensus forecast for 2027 implies product revenue growth of just 9%, with some investors questioning whether Fortinet can deliver any growth as comparisons become more demanding.
Management has previously outlined a framework for annual product revenue growth of 10% to 15%, while Jefferies believes the current replacement cycle could have further room to run.
Fortinet has recorded three quarters of product growth above 20% during the current cycle, compared with 10 quarters during the pandemic-era refresh cycle, suggesting that replacement demand may continue to support results.
Recent price increases should also provide a tailwind into the first quarter of 2027, with average selling prices potentially rising by more than 10% in the second half, although growth will increasingly depend on underlying demand as those increases feed through.
Jefferies also expects third-quarter billings, a measure of customer orders invoiced, to exceed expectations by a mid-to-high single-digit percentage, against guidance implying growth of 27% at the midpoint.
Investors will also watch current services billings, which Jefferies expects to accelerate from 16% annual growth in the second quarter, with growth above 20% still achievable as product sales generate follow-on service revenue.
Despite the positive near-term outlook, Jefferies warned that tougher comparisons could constrain further upside until Fortinet provides clearer evidence of sustainable growth in 2027.
The broker noted that Fortinet trades at 37 times the estimated calendar 2027 free cash flow, below Palo Alto Networks at 50 times and broadly in line with Zscaler at 36 times.
No Investment Advice
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
